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ABSTRACT  
A High-throughput screen (HTS) was undertaken against the respiratory chain dehydrogenase 
component, NADH:menaquinone oxidoreductase (Ndh) of Mycobacterium tuberculosis (Mtb). 
11,000 compounds were selected for the HTS based on the known phenothiazine Ndh inhibitors, 
trifluoperazine and thioridazine. Combined HTS (11,000 compounds) and in-house screening of a 
limited number of quinolones (50 compounds) identified ~100 hits and four distinct chemotypes, 
the most promising of which contained the quinolone core. Subsequent Mtb screening of the 
complete in-house quinolone library (350 compounds) identified a further ~90 hits across three 
quinolone sub-templates. Quinolones containing the amine based side chain were selected as the 
pharmacophore for further modification, resulting in metabolically stable quinolones effective 
against multi drug resistant (MDR) Mtb. The lead compound, MTC420 displays acceptable anti-
tuberculosis activity (Mtb IC50 =525 nM, Mtb Wayne IC50 = 76 nM and MDR Mtb patient isolates 
IC50 = 140 nM) and favourable pharmacokinetic and toxicological profiles.   
 
INTRODUCTION 
In 2014 tuberculosis (TB) globally infected 9.6 million people resulting in an estimated 1.5 million 
deaths.1 With the emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) 
TB the need for new drug treatments targeting the disease has never been greater.2 Current first 
line drugs for TB were developed in 1952-1966 (Figure 1).  Shortcomings of these drugs include; 
(i) long treatment regimens (6 to 9 months) leading to patient non-compliance, (ii) adverse drug-
drug interactions with anti HIV drugs (HIV/AIDS is a common co-infection) and (iii) limited or 
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no activity against MDR and XDR Mycobacterium tuberculosis (Mtb).3 Bedaquiline 4, 5 and 
delamanid 6, 7 are the only recently FDA approved drugs for the treatment of TB and their approval 
is currently only for MDR in cases where established treatments have failed (Figure 1).8 In order 
to find an effective treatment for MDR and XDR it is believed that a drug with a novel mode of 
action is required in order to circumvent resistance. 
 
Figure 1. Current first line drugs used to treat tuberculosis and recently approved drugs for the 
treatment of MDR TB. 
Targeting components of the Mtb respiratory chain (Figure 2) has been shown by us and other 
laboratories, to be effective in sterilizing both replicating and dormant Mtb.9-18 The initial target 
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within this programme, Ndh (Rv1854c) is a single subunit 50 KDa enzyme involved in the redox 
reaction of NADH oxidation with subsequent menaquinol production. Ndh has been biochemically 
identified as a “choke point” and as such is essential for cell function and viability. 19   Essentiality 
of ndh has been shown by the inability of Mtb to tolerate insertion mutations in this gene20  and 
more recently in a study involving ndh knockout with subsequent confirmation by 
complementation.21 The other NADH-dependent electron donating dehydrogenases identified in 
the genome (Complex I and ndhA) have been shown not to be lethal.18, 22 These data are consistent 
with biochemical evidence that Ndh is a major source of electrons for the ETC. 
 
 
Figure 2. Schematic representation of the respiratory chain of M. tuberculosis. The chain 
components are Ndh/NdhA – type II NADH:(mena)quinone oxidoreductase (two isoforms), ETF 
– electron transferring flavoprotein (transfer of reducing equivalents from fatty acid β-oxidation 
into the Q-pool), nuo – protonmotive NADH dehydrogenase (Complex I), bcc – cytochrome bcc 
complex (note that there is no evidence for soluble cytochrome c in this organism), aa3 – 
cytochrome bcc oxidase, postulated to form a supercomplex with bcc. An alternative terminal 
oxidase pathway is utilised in M. tuberculosis under conditions of low oxygen tension, containing 
quinol oxidase (cytochrome bd), fumarate reductase (FRD) and nitrate reductase (nar) 
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components. P and n correspond to the positive and negative sides of the respiratory membrane 
with respect to proton translocation. Proton movements are indicative only, and do not represent 
H+/e- ratios for the respective complexes. 
Respiratory-chain inhibition-induced death represents a fundamental shift from traditional anti-
tubercular drug design that have until recently relied on drugs that selectively target the replication 
machinery of Mtb. 9, 23-28 Anti-tubercular drugs developed to target the respiratory pathways should 
therefore have the potential to have sterilizing activity against current MDR and XDR Mtb strains.  
Identification of hit compounds was achieved through a HTS screen of approximately 11,000 
compounds that were predicted to possess activity against the Ndh enzyme. Ndh was chosen for 
the HTS due to the critical role as an important dehydrogenase during growth and pathogenicity9, 
17 and due to its tractability for heterologous expression in E.coli and HTS29. The enzyme has been 
observed to be sensitive to phenothiazine-based inhibitors such as trifluoperazine and 
thioridazine9. These inhibitors have been shown by a number of different laboratories to have 
sterilizing activity against replicating and slow growing MDR Mtb (grown anaerobically) in both 
in vitro and in vivo models.14, 30, 31 These two compounds were used as the basis to employ a range 
of ligand-based chemoinformatics methods32-35 in the rational selection of the ~11,000 compounds 
for the HTS campaign (selected from a commercial library of ~750,000 compounds (Biofocus 
DPI)).36-40  Selected compounds were subject to a sequential high throughput screening campaign 
using an in vitro assay against recombinant Ndh as described previously.29  
In addition to the HTS screen a limited selection of 50 quinolones were also screened in-house 
against Mtb Ndh. These compounds were selected for their structural diversity from a library of 
quinolones designed to target the NADH:ubiquinone oxidoreductase within the malaria parasite 
Plasmodium falciparum (PfNDH2) as described previously.41-44 The HTS screen and in-house 
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screen in combination generated ~100 hits across 4 distinct templates, the most potent of which 
were also tested for whole cell replicating Mtb activity. Following analysis of the in vitro biological 
data, predicted DMPK properties and investigations into chemical tractability the quinolone 
template was selected as the most promising for further development.  
In previous antimalarial discovery projects41-48, the inhibitors based on the quinolone core 
displayed pharmacodynamics consistent of a privileged pharmacophore, with the ability to act on 
multiple electron transport chain (ETC) components.  For example, quinolones with a dual 
mechanism of action against two respiratory enzymes, PfNDH2 and cytochrome bc1 have recently 
been reported. 43 To exploit this phenomenon in this antitubercular discovery project, further 
screening and SAR investigations was switched to whole cell replicating TB activity. In order to 
fully establish the structure activity relationship (SAR) within the existing quinolone library with 
respect to whole cell Mtb activity a further library of ~350 compounds were screened against 
replicating Mtb. ~90 compounds were found to inhibit Mtb growth by >50% at 5 µM. Four sub-
templates were then identified as having moderate in vitro Mtb potency. The most promising of 
which only had a very limited number of examples (see Table S1 – Supporting Information) within 
the existing library but demonstrated significantly more potency, as such the template based on 
compounds 1 and 2 was chosen for lead optimisation (Figure 3). 
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Figure 3. Identification of the quinolone template for lead optimisation.  
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A comprehensive medicinal chemistry SAR study around this series was then undertaken to 
establish optimised leads for further development. Screening data analysis (see Table S1 – 
Supplementary Information) shows NH2 and OAc at the 4-position are inactive for this particular 
sub-template (Table S1 - entries 20, 23 and 24) and show reduced activity for other quinolone sub-
templates. Replacement of the phenyl ring with a pyridyl ring also rendered the sub-template 
inactive (Table S1 - entry 20). Modification of ring C resulting in loss of in vitro Mtb potency is a 
general trend that was seen across most quinolone sub-templates screened. Modifications of 
particular interest were therefore optimization of the side chain to optimize potency and DMPK, 
the nature of the group at 3-position and the electronic/steric effect of substituents placed at the 5, 
6 and 7 positions (Figure 4). 
 
Figure 4. Known SAR and SAR to be investigated. 
CHEMISTRY 
Following identification of quinolones 1 and 2 as the initial hits against Mtb, our initial efforts 
were focused on exploring the SAR of substituents placed in the A ring. The synthesis of these 
compounds was achieved in 3 – 5 steps from commercially available starting materials (Scheme 
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1). Oxazoline 4 was prepared from the corresponding isatoic anhydride 3 in yields of 34 – 75%. 
Where the isatoic anhydride was not commercially available, the oxazolines were synthesized in-
house (see Supporting information). 4’-fluoropropiophenone 5 was reacted with piperidine to give 
ketone 6 in 32 – 97% yields. Reaction of oxazoline 4 with ketone 6 in the presence of triflic acid 
gave the desired quinolones 1, 2, 7a-k in 23 – 45% yields.  
Scheme 1. Synthesis of Quinolones 1, 2, 7a-k.a 
 
a Conditions and reagents: (a) 2-amino-2-methyl-propanol, ZnCl2, PhCl, 135
 oC, 24 h; (b) 
corresponding amine, K2CO3, DMF, 120
oC to reflux,  overnight ; (c) CF3SO3H, n-BuOH, N2, 130
 
oC, 24 h.  
Table 1. Yields for the Synthesis of Compounds 1, 2, 7a-k. 
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Compound X R % yield 4 % yield 6 % yield 7 
 
1 H H - 62 23 
2 7-OMe H 75 62 36 
7a 6-F H 60 62 26 
7b 6-OMe, 7-OMe H 52 62 28 
7c 6-Cl,  7-OMe H 45 62 35 
7d 6-F,    7-OMe H 52 62 41 
7e 5-OMe, 7-OMe H 58 62 32 
7f 5-F,7-F H 68 62 45 
7g 7-F H - 62 35 
7h 7-Cl H 64 62 37 
7i H F - 55 36 
7j 7-OMe F 75 55 43 
7k 5-F,7-F F 68 55 29 
 
The nature of the group at 3-position of the quinolone was also studied. A small set of analogues 
with a hydrogen at 3-position were synthesized (Scheme 2). Substituted 2-aminoacetophenone 9 
was converted from the respective aminobenzoic acid 8 using methyl lithium in 36% yield. 4-
fluorobenzoate 10 was reacted with piperidine in the presence of potassium carbonate to give the 
piperidinyl benzoate 11 in 37% yield. Benzoate 11 was hydrolysed to benzoic acid which was then 
converted to acid chloride 12 by oxalyl chloride. Acylation of 2-aminoacetophenone 9 with acid 
chloride 12 provided the intermediate 13 in 30 – 51% yields. Cyclisation of the intermediate 13 in 
the presence of NaOH or KOtBu gave the 3-H quinolones 14a-c in 41 – 91% yields (Table 2).  
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Literature precedent from the development of ETC inhibitors in the antimalarial field lead us then 
to look at the presence of a halide at the 3-position. GSK’s pyridone series 49 demonstrated 
tolerance of the presence of a chlorine at 3-position and within our own group we have shown the 
combination of 3-chloro-7-methoxy enhances biological activity of the quinolone core.50 In order 
to achieve this the 3-H compounds were treated with sodium dichloroisocyanurate and sodium 
hydroxide to give 3-Cl quinolones 15a-d in 40 – 61% yields, or NBS to give 3-Br quinolones 15e-
f in 55 – 63% yields.  
Scheme 2. Synthesis of quinolones 14 a-c and 15 a-f.a 
 
a Conditions and reagents: (a) MeLi, DME, 0oC, 2 h; (b) (i) K2CO3, DMF, reflux, overnight, (ii) 
NaOH (aq), MeOH, reflux, overnight; (c) oxalyl chloride, DCM, DMF (cat.), r.t., 2 h; (d) NEt3, 
THF, r.t., overnight; (e) NaOH (s), 1,4-dioxane, 110oC, 5 h or KOtBu, tBuOH, 75oC, 16 h; (f) 
sodium dichloroisocyanurate, 1M NaOH (aq), MeOH, r.t., overnight (15a-d) or NBS, DCM, DMF, 
r.t., overnight (15e-f).  
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Table 2. Yields for the Synthesis of Compounds 14a-c and 15a-f. 
 
Compound  X R Y % yield 
9 
% yield 
11 
% yield 
13 
% yield 
14 
% yield 
15 
14a H H H - - 51 70 - 
14b OMe H H 36 - 50 41 - 
14c OMe F H 36 37 30 68 - 
15a H H Cl - - 51 70 40 
15b OMe H Cl 36 - 50 41 61 
15c OMe F Cl 36 37 30 68 52 
15d H F Cl - 37 60 91 58 
15e H H Br - - 51 70 63 
15f H F Br - 37 60 91 55 
 
Having identified 3-methyl and 5, 7-difluoro quinolone (followed by 6-fluoro-7-methoxy and 7-
methoxy quinolone) to be optimal for Mtb activity (see Table 8), the focus of SAR explorations 
moved to the terminal ring of the side chain to further improve Mtb activity and optimise DMPK. 
Additional small groups, such as Me, F and CF3 attached at different positions on the terminal 
piperidine ring were investigated. In addition the effect of chirality was explored.51 Synthesis of 
compounds 17a-k was achieved using chemistry described in Scheme 3.  
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Scheme 3. Synthesis of Quinolones 17a-k.a 
 
a Conditions and reagents: (a) corresponding amine, K2CO3, DMF, 120
oC to reflux, overnight ; (b) 
CF3SO3H, n-BuOH, N2, 130
 oC, 24 h.  
Table 3. Yields for the Synthesis of Compounds 17a-k. 
 
Compound R % Yield 16 % Yield 17 
17a 
 
48 32 
17b 
 
73 54 
17c 
 
48 34 
17d 
 
40 57 
17e 
 
64 27 
17f 
 
84 45 
17g 
 
74 43 
17h 
 
75 40 
17i 
 
72 39 
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Incorporation of different amino groups into the side chain as an alternative to the potentially 
metabolically labile piperidine ring was also investigated. To incorporate a diethylamine group an 
alternative methodology was used to synthesise the side chain, commercial available 4-bromo-
N,N-dimethylaniline 18 was treated with butyllithium for a lithium-halogen exchange and the 
intermediate was quenched with N,N-dimethylpropionamide to form the side chain 19 in 78% 
yield, reaction with oxazoline 4h was then carried out to give quinolone 17l in 46% yield (Scheme 
4).  
Scheme 4. Synthesis of quinolone 17l.a 
 
a Conditions and reagents: (a) (i) nBuLi, Et2O, -78
oC, 30 min; (ii) N,N-dimethylpropionamide, -
78oC to r.t., 2 h; (b) CF3SO3H, n-BuOH, N2, 130
 oC, 24 h. 
Extension of the side chain with a phenyl or benzyl group at the 2-position was also investigated 
using the synthetic methodologies shown in Scheme 5. In addition, replacement of piperidine by 
piperazine was investigated. This was to further explore the length of side chain that could be 
tolerated and to improve the solubility.  
17j 
 
69 41 
17k 
 
-NHCH2Ph 28 51 
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Scheme 5. Synthesis of Quinolones 21a-g.a 
 
a Conditions and reagents: (a) corresponding amine, K2CO3, DMF, 120
oC to reflux, overnight; (b) 
CF3SO3H, n-BuOH, N2, 130
 oC, 24 h.  
Table 4. Yields for the Synthesis of Compounds 21a-g. 
 
Compound X A B % Yield 20 % Yield 21 
21a H CH CH2Ph 64 33 
21b 6-F CH CH2Ph 64 40 
21c 7-OMe CH CH2Ph 64 42 
21d H N CH2Ph 58 30 
21e 6-F N CH2Ph 58 28 
21f 7-OMe N Ph 64 30 
21g 7-OMe N CH2Ph 58 38 
 
In addition, the quinolone with a piperidine ring at the meta-position 24 was also synthesised by 
reacting the 3-bromopropiophenone 22 with piperidine using Buchwald coupling to yield the 
ketone intermediate 23, which was coupled with oxazoline 4h to give the quinolone in 45% yield 
(Scheme 6).  
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Scheme 6. Synthesis of Quinolone 24.a 
 
a Conditions and reagents: (a) Piperidine, Pd(OAc)2, XPhos, NaO
tBu, Toluene, 110 oC, 24 h; (b) 
CF3SO3H, n-BuOH, N2, 130
 oC, 24 h. 
A series of analogues with a pyrrole heterocycle in the side chain were also synthesized to further 
explore the side chain SAR and enhance the metabolic stability. The synthetic route to these 
compounds is illustrated in Scheme 7. Utilizing Copper and trans-N,N’-Dimethyl-
1,2cyclohexanediamine catalyzed N-arylation with 4-bromopropiophenone the side chain ketone 
intermediate 31 was formed in 30 – 62 % yields.52, 53 Final cyclisation with oxazoline gave 
quinolones 32a-g in 35 – 57% yields.  
Scheme 7. Synthesis of quinolones 32a-g.a 
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a Conditions and reagents: (a) EtMgBr, THF, 0 oC, 1h; (b) PCC, DCM, r.t., 2h; (c) 5mol% CuI, 
20mol% trans-N,N’-Dimethyl-1,2cyclohexanediamine, K3PO4, Toluene, 110oC, 24 h; (d) 
CF3SO3H, n-BuOH, N2, 130
 oC, 24 h.  
Table 5. Yields for the Synthesis of Compounds 32a-g. 
 
Compound X  Y R % yield 31 % yield 32 
32a 5-F,7-F - 
 
38 55 
32b 5-F,7-F - 
 
30 57 
32c 5-F,7-F - 
 
46 35 
32d 5-F - 
 
62 32 
32e 5-F,7-F - 
 
62 30 
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32f 5-F,7-F m-Cl 
 
49 39 
32g 5-F,7-F o-F 
 
52 39 
 
Using fluorine to block metabolism and improve oral absorptions was further explored. Research 
by Smith has shown that gem-difluorinated piperidine compounds exhibited a significant 
improvement in metabolic stability.54 This led to the design and synthesis of fluorinated quinolones 
38a-f as well as the alcohol side chain quinolones 38g-i. The chemistry used in the synthesis of 
these compounds is shown in Scheme 8.  
Scheme 8. Synthesis of Quinolones 38a-l.a 
 
a Conditions and reagents: (a) corresponding amine, K2CO3, DMF, 120
oC to reflux, overnight; (b) 
CF3SO3H, n-BuOH, N2, 130
 oC, 24 h.  
Table 6. Yields for the Synthesis of Compounds 38a-l. 
 
Compound X R % Yield 37 % Yield 38 
38a 
 
5-F,7-F 
 
38 45 
38b 
 
5-F,7-F 
 
37 47 
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38c 
 
5-F,7-F 
 
25 33 
38d 
 
5-F,7-F 
 
32 30 
38e 
 
7-OMe 
 
32 32 
38f 
 
6-Cl,7-OMe 
 
32 30 
38g 
 
5-F,7-F 
 
69 48 
38h 
 
5-F,7-F 
 
54 50 
38i 
 
5-F,7-F 
 
32 43 
38j 5-F,7-F 
 
41 20 
38k 5-F,7-F 
 
43 25 
38l 5-F,7-F 
 
41 37 
 
Removal of the benzyl group from the chiral proline derivatives 38j-l was achieved using 
hydrogenation (Scheme 9) in good yields. 
Scheme 9. Synthesis of compounds 39a-c. 
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For the gem-difluoro analogues (42a (MTC420)  and 42b), 4-bromopropiophenone was first 
converted to a more reactive 4-iodopropiophenone by an aromatic Finkelstein reaction catalysed 
by copper(I) iodide in combination with N,N-dimethyl-1,2-diaminoethane.55 A subsequent 
Buchwald-Hartwig amination using Pd2(dba)3 and Xantphos with the gem-fluorinated amine gave 
the ketone side chain 41a-b in 12 – 28% yields.56 Reaction with oxazoline gave quinolones 42a-b 
in 47 – 56% yields (Scheme 10).  
Scheme 10. Synthesis of quinolones 42a-b.a 
 
a Conditions and reagents: (a) CuI, N,N-dimethyl-1,2-diaminoethane, NaI, 1,4-dioxane, 110oC, 24 
h; (b) Pd2(dba)3, Xantphos, NaO
tBu, 1,4-dioxane, 110oC, 24 h; (c) CF3SO3H, n-BuOH, N2, 130
 
oC, 24 h. 
42a was identified as the lead compound in the series as it exhibited good potency and metabolic 
stability (See Table 11 and Table 12), further investigation of the pyrrolidine side chain was 
undertaken to improve solubility and potency.  Further modifications have included adding 
chirality and introducing amide functionality to rapidly ascertain if it is tolerated within the 
template. Quinolones 45a-h were therefore synthesised using chemistry described in Scheme 11. 
To incorporate the amide group, Ullmann coupling of 4-bromopropiophenone with D-proline gave 
the carboxylic acid intermediate 43a-b. Crosslinking the carboxylic acid by EDC/NHS to 
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respective amine provided the ketone side chain 44 in 52 – 90% yields. This was subsequently 
coupled with oxazoline in 12 – 34% yields to afford quinolones 45a-g.  
Scheme 11. Synthesis of Quinolones 45a-g.a 
 
a Conditions and reagents: (a) D-proline, CuI, K2CO3, DMF, 140
oC, 24 h; (b) (i) EDC, N-
hydroxysuccinamide, CHCl3, NEt3, amine, r.t., 6 h; (ii) amine, NEt3, r.t., 2h; (c) CF3SO3H, n-
BuOH, N2, 130
 oC, 24 h.  
Table 7. Yields for the Synthesis of Compounds 45a-g. 
 
Compound R n % yield 44 % yield 45 
45a -NHtBu 2 52 20 
45b -NEt2 2 80 34 
45c 
 
2 90 25 
45d 
 
2 70 18 
45e 
 
2 65 24 
45f -NMe2 1 45
a 15 
 22 
45g -NHtBu 1 -b 12 
aAlternative methodology used please see supporting information. b Used crude. 
Incorporation of an amide moiety largely resulted in reduced anti-tuberculosis activity (Table 7). 
As such our attention returned to 42a and improving its pharmacokinetic profile. Use of a pro-drug 
strategy, previously used successfully within other quinolone development programs57 was 
investigated leading to the synthesis of compound 46. Compound 46 was synthesized by reacting 
42a with potassium tert-butoxide and acetyl chloride to give the acetate pro-drug in high yield.  
Scheme 12. Synthesis of pro-drug 46. a 
 
a (a) i. tBuOK, THF, r.t., 1h. ii. Acetyl chloride, r.t., 3h.  
RESULTS AND DISCUSSION 
Structure Activity Relationships (SAR) - Initial SAR investigations around the hit compounds 1 
and 2 focused on establishing the optimal A-ring substituents (X). Compounds 1, 2 and 7a-7h 
demonstrate the most favorable X groups are 5-F, 7-F closely followed by 6-F, 7-OMe and 7-
OMe. Compounds 7i-7k were synthesised with a view to reducing the potential metabolism of the 
piperidine ring. Pleasingly a good level of potency was maintained. Concomitantly the potential 
for replacing the methyl group at Y was also investigated. When Y=H activity is lost as 
demonstrated by compounds 14a-c. Halogenation was also investigated; again this largely resulted 
in reduced anti-tuberculosis activity (15a-f). The one exception to this being 15e possessing a Br 
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at Y. This affect appeared to be compound specific rather than a general trend across all brominated 
analogues and as such it was decided that the methyl group was the optimal group at this position. 
Table 8. Mtb IC50 values for compounds 1, 2, 7a-k, 14a-c and 15a-f. 
 
Compound X Y R Mtb IC50 (µM) 
1 H Me H 1.50 ± 0.19 
2 7-OMe Me H 0.73 ± 0.01 
7a 6-F Me H 1.83 ± 0.22 
7b 6-OMe, 7-OMe Me H >10 
7c 6-Cl, 7-OMe Me H >10 
7d 6-F, 7-OMe Me H 0.52 ± 0.06 
7e 5-OMe, 7-OMe Me H >10 
7f 5-F, 7-F Me H 0.27 ± 0.08 
7g 7-F Me H >10 
7h 7-Cl Me H >10 
7i H Me F >10 
7j 7-OMe Me F 1.32 ± 0.10 
7k 5-F, 7-F Me F 0.94 ± 0.12 
14a H H H >10 
14b 7-OMe H H >10 
14c 7-OMe H F >10 
15a H Cl H 1.56 ± 0.22 
15b 7-OMe Cl H 2.82 ± 0.21 
15c 7-OMe Cl F >10 
15d H Cl F >10 
15e H Br H 0.60 ± 0.09 
15f H Br F >10 
 
With 5-F, 7-F and 3-methyl confirmed as optimal for anti-tuberculosis activity optimising the side 
chain then became the focus of the SAR studies (Table 9). Initial investigations into piperidine 
ring substituents at the 4-position revealed that in addition to 4-F 7k, a methyl group is also 
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tolerated as demonstrated with compound 17b. It rapidly became apparent that there was a size 
limitation to the group tolerated at the 4-position with larger groups such as CF3, cyclopropyl and 
gem-difluoro resulting in loss of potency. Movement of the F and Me groups to the 3-position 
resulted in improvements in anti-tuberculosis activity as demonstrated by compounds 17e-h. 
Interestingly racemic and enatiomerically pure analogues of the 3-methyl derivative 17f showed 
little variation in potency, which is in direct contrast to the pyrrolidine analogues discussed later. 
Replacement of the piperidine ring with a number of alternative amines was also investigated. 
Increasing ring size (17j) and use of dimethyl amine (17l) retained good potency. Incorporation of 
secondary amines (17k) and more polar groups such as N-methyl piperazine (17i) reduced anti-
tuberculosis activity. Moving the piperidine group from the para to the meta-position (24) also 
resulted in loss of activity. 
Table 9. Mtb IC50 values for compounds 17a-l and 24. 
 
 
Compound R Mtb IC50 (µM) Compound R Mtb IC50 (µM) 
17a 
 
>10 17h 
 
0.47 ± 0.02 
17b 
 
0.61 ± 0.05 17i 
 
>10 
17c 
 
>10 17j 
 
0.49 ± 0-07 
17d 
 
>10 
17k 
 
-NHCH2Ph 
>10 
17e 
 
0.31 ± 0.03 17l 
 
0.41 ± 0.002 
17f 
 
0.37 ± 0.04 24 
meta >10 
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17g 
 
0.47 ± 0.03    
 
The size limitation and unfavorable incorporation of piperazine was further confirmed by our 
concomitant investigation in to extended side chain analogues (Table 10). The aim of this series 
was to explore the space available and to improve solubility with the incorporation of piperazine 
to facilitate salt based formulation. 
Table 10. Mtb IC50 values for compounds 21a-g. 
 
Compound X A B Mtb IC50 (µM) 
21a H CH CH2Ph >10 
21b 6-F CH CH2Ph >10 
21c 7-OMe CH CH2Ph >10 
21d H N CH2Ph 5.74 ± 0.66 
21e 6-F N CH2Ph >10 
21f 7-OMe N Ph >10 
21g 7-OMe N CH2Ph >10 
 
With this information in hand several small heterocyclic, fluorinated, chiral and amide analogues 
were synthesized to investigate SAR and improve DMPK (Table 11). Compounds 32a-g are 
pyrrole derivatives. An unsubstituted pyrrole moiety is well tolerated in the 5-F (32d) and 5-F, 7-
F (32e) analogues, however increasing the size of the pyrrole group by addition of a fused benzene 
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ring (32b) again results in loss of potency. Incorporation of a halogen on the aromatic ring was 
also investigated but reduced potency.  
Table 11. Mtb IC50 values for compounds 32a-g, 38a-j, 39a-c, 42a-b and 45a-g. 
 
Compound X R Mtb 
IC50 
(µM) 
Compound X R Mtb 
IC50 
(µM) 
32a 5-F,7-F 
 
>10 38i 
 
5-F,7-F 
 
>10 
32b 5-F,7-F 
 
>10 38j 5-F,7-F 
 
0.96 ± 
0.06 
32c 5-F,7-F 
 
>10 39a 5-F,7-F 
 
1.59 ± 
0.05 
32d 5-F 
 
0.71 ± 
0.05 
39b 5-F,7-F 
 
0.32 ± 
0.04 
32e 5-F,7-F 
 
0.44 ± 
0.02 
39c 5-F,7-F 
 
>10 
32f 5-F,7-F 
Y= m-Cl  
>10 42a 5-F,7-F 
 
0.53 ± 
0.08 
32g 5-F,7-F 
Y= o-F  
>10 42b 5-F,7-F 
 
0.36 ± 
0.04 
38a 
 
5-F,7-F 
 
0.23 ± 
0.003 
45a 5-F,7-F 
 
0.96 ± 
0.05 
38b 
 
 
5-F,7-F 
 
1.80 ± 
0.09 
45b 5-F,7-F 
 
>10 
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38c 
 
 
5-F,7-F 
 
1.53 ± 
0.04 
45c 5-F,7-F 
 
>10 
38d 
 
 
5-F,7-F 
 
>10 45d 5-F,7-F 
 
>10 
38e 
 
 
7-OMe 
 
>10 45e 5-F,7-F 
 
>10 
38f 
 
 
6-Cl,7-OMe 
 
>10 45f 5-F,7-F 
 
>10 
38g 
 
 
5-F,7-F 
 
5.01 ± 
0.03 
45g 5-F,7-F 
 
>10 
38h 
 
 
5-F,7-F 
 
>10     
 
Fluorinated analogues were synthesized in order to improve metabolic stability (see Table 11). 
Both mono (38a and 38b) and gem-difluoro (42a) substituted pyrrolidine derivatives exhibited 
good to excellent potency. The gem-difluoro azetidine (38c) and 3-substituted piperidine (42b) 
also demonstrated good potency. Incorporation of an alcohol group in the side chain to reduce 
lipophilicity and potentially facilitate pro-drug approaches provided mixed results. Gem-methyl, 
OH analogues 38g-i were not tolerated whereas inclusion of prolinol (39a-b) gave good anti-
tuberculosis activity. Benzylated analogue 38j and amide analogues 45a-g largely resulted in loss 
of potency. For the pyrrolidine analogues the effect of chirality on activity was marked with the 
(R)-3-fluoro analogue 38a (Mtb IC50 = 0.23 µM) demonstrating significantly superior potency over 
the (S)-3-fluoro analogue 38b (Mtb IC50 = 1.80 µM). The effect of chirality was also observed 
with the prolinol analogues, (S)-prolinol analogue 39b (Mtb IC50 = 0.32 µM) being more active 
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than (R)-prolinol analogue 39a (Mtb IC50 = 1.52 µM). The overall SAR trends for the series can 
be seen in Figure 5. 
 
Figure 5. Overall SAR trends for the heterocyclic quinolone series. 
In vitro DMPK and toxicity - Analogues demonstrating good potency were then moved through 
our screening cascade and evaluated for microsomal turnover and HEPG2 cytotoxicity. None of 
the compounds were found to be cytotoxic and all had good therapeutic indexes. From the earlier 
analogues tested (entries 1-6 in Table 12) it was apparent that the compounds were being 
metabolised quickly by liver microsomes. Resolving this issue was therefore the driving force for 
a large proportion of the medicinal chemistry manipulations described in Table 11 above. 
Table 12. HEPG2 and microsomal turnover t1/2 for selected analogues. 
Compound Mtb 
IC50 
(µM) 
Mtb 
IC90 
(µM) 
HEPG2 
GLU 
(µM) 
Therapeutic 
Index 
Microsomal 
Turnover (h, m, 
r) t1/2 (min) 
7f 0.270 ± 
0.080 
0.78 >100 >370 h-7.31 
m-8.27 
r-8.30 
7k 0.950 ± 
0.120 
1.83 102.2 108 h-5.7 
m-4.4 
r-8.4 
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17b 0.611 ± 
0.048 
 
1.93 >100 >164 h-<10 
m-<10 
r-<10 
17e 0.300 ± 
0.025 
0.56 188.1 627 h-7.8 
m-6.8 
r-10.1 
17f 0.367 ± 
0.040 
 
0.63 >100 >272 h-7.9 
m-22.3 
r-10.8 
17h 0.400 ± 
0.023 
0.66 85.54 223 h-8.54 
m-7.65 
r- 5.72 
32e 0.432 ± 
0.020 
 
0.69 141 342 h-10.2 
m-20.7 
r-30.1 
38a 0.231 ± 
0.036 
0.50 150.6 649 h-10.2 
m-4.4 
r-10.6 
38d                        >10 >10 ND ND h-60 
m-60 
r-60 
42a 0.525 ± 
0.080 
1.10 >100 >190 h-72.8 
m-114.9 
r-61.6 
42b 0.361 ± 
0.041 
0.83 ND ND h-17.4 
m-16.2 
r-13.7 
 
Two strategies were employed to address the metabolic stability issues (Figure 6). The first was to 
replace the piperidine ring with an alternative heterocycle. Amongst those selected pyrrole (32e) 
provided the most active compound with a modest improvement in metabolic stability. 
Fluorination of the pyrrole (38d) at the 3 and 4 positions resulted in complete resolution of 
metabolic instability; however anti-tuberculosis activity was also lost. From earlier SAR studies 
we knew that replacing the piperidine ring (7f) with a pyrrolidine ring (17l) was tolerated in terms 
of activity and may provide us with more opportunity to modify the ring in what we believe to be 
a limited space.  Mono-fluorination (38a) provided a very modest improvement in stability. 
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Subsequent synthesis of the gem-difluoro analogue (42a) however provided us with a compound 
with both good anti-tuberculosis activity and excellent metabolic stability. The equivalent six 
membered ring analogue 42b had good potency but comparatively decreased metabolic stability 
as expected (Table 12). 
Figure 6. Resolution of metabolic stability problems. 
Selected analogues were also measured for Caco-2 permeability, stability in plasma, % plasma 
protein binding (PPB) and solubility (Table 13). All compounds performed well in these assays 
with the exception of solubility which is a common issue for the quinolone chemotype.  
Table 13. Caco-2 permeability, stability in plasma, % PPB and solubility values for selected 
analogues. 
Compound Caco-2 
permeability 
(cm-1/s) 
Stability in 
plasma (r,h) 
T1/2 (min) 
Human 
PPB 
(%) 
Solubility 
(µg/mL) 
              
pH1  pH7.4  CMa 
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5k ND r->180 
h->180 
95.82 >150 <1 12 
17e 22.86 x 10-6 r->180 
h->180  
98.45 >150 <1 10 
32e 30.97 x 10-6 r->180 
h->180 
96.1 
 
5.1 3.6 61 
38b 15.51 x 10-6 r->180 
h->180 
98.97 <1 <1 2.5 
42a 10.00 x 10-6 r->180 
h->180 
97.30 < 1  < 1  55  
a CM – culture media - Middlebrook 7H9 broth with addition of 10% albumin–dextrose–catalase 
solution (Becton Dickinson), 0.2% [vol/vol] glycerol and 0.05% [vol/vol] Tween 80. 
A number of analogues also underwent additional in vitro DMPK (Table 14) experiments further 
confirming the metabolism issues detailed above. 
Table 14. In vitro DMPK measurements for selected analogues. 
Compound Aqueous 
Solubility 
(µM) 
Human 
% PPB 
LogD7.4 Human 
Microsomes 
CLint 
(µL/min/mg) 
Rat Hepatocytes 
CLint 
(µL/min/106cells) 
7d 2 98.8 3.9 > 300.0 231.3 
15b 0.5 98.8 3.6 > 300.0 48.9 
17g < 0.5 99.5 4.7 > 300.0 183.4 
17h < 0.3 99.3 > 3.2 > 300.0 91.2 
17j < 0.1 99.4 4.8 > 300.0 243.4 
38a 0.9 99.1 3.8 174.9 117.6 
38b 1 98.6 3.6 197.4 150.1 
39a 4 95.5 > 3.4 > 300.0 36.5 
39b 4 95.5 > 3.4 > 300.0 36.5 
42a 0.2 99.7 4 89.7 52.2 
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Biological profile - Having selected 42a as the lead compound, full biological profiling was 
undertaken to establish its pharmacokinetic and toxicological profile in addition to its activity 
against slow-growing (Wayne assay) and MDR-resistant Mtb (Table 15). 
Table 15. Biological profile of 42a. 
 
In vitro anti-tuberculosis activity  
Replicating sensitive Mtb IC50 (µM) 0.525  
Replicating sensitive Mtb IC90 (µM) 1.10 
Dormant (Wayne Model) Mtb IC90 (µM) 0.076  
MDR Mtb (05TB42059) IC50 (µM)  0.140  
MDR Mtb (DQ707(S315N kat G)) IC50 (µM) 0.548 
In vitro DMPK  
Microsomal Turnover (h, m, r) T1/2 (min) h-72.8, m-114.9, r-61.6 
Microsomal Clint (h, m, r) (µL/min/mg) h-9.52, m-6.03, r-11.25 
Caco-2 permeability (cm-1/s) A to B 10.00 x 10-6 
Caco-2 permeability (cm-1/s) B to A 9.8 x 10-6 
Stability in plasma (r,h) T1/2 (min) r->180, h->180 
Human % PPB 97.30 
Solubility (µg/mL) pH1, pH7.4, CM <1, <1, 55 
CYP2C8 Inhibition (% at 10 µM) 38 
CYP2C9 Inhibition (% at 10 µM) 0 
CYP2D6 Inhibition (% at 10 µM) 0 
CYP3A4 Inhibition (% at 10 µM) 0 
CYP3A5 Inhibition (% at 10 µM) 0 
In vitro toxicity  
HEPG2 IC50 GLU (µM) >100 
TI >190 
hERG IC50 (µM) >25 
Ames -ve 
 
 33 
42a demonstrated comparable activity against all tested strains of sensitive and MDR Mtb as well 
as having good potency against dormant, non-replicating TB. It demonstrated a suitable in vitro 
DMPK and toxicity profile to undergo in vivo pharmacokinetic analysis. 
Pharmacokinetics - the pharmacokinetic profile of 42a can be seen in Figure 7 and Table 16. 
Analysis of data from the parent compound indicated solubility limited absorption as the PK did 
not increase linearly with dose from 10 mg/kg to 50 mg/kg. At this point the acetate pro-drug 
strategy was deployed in an attempt to improve exposure. 
 
Figure 7. Pharmacokinetics after oral dosing of 42a (a.), 46 (b.) and an overlay of both (c.) 
Table 16. Pharmacokinetic parameters for 42a and 46. 
 34 
 
Parent 42a Prodrug 46* 
Dose (mg/kg)  0.5 (iv) 10 (po) 50 (po) 10 (po) 50 (po) 
 
T1/2 (h) 
 
1.48 
 
3.8 
 
4.2 
 
3.9 
 
2.3 
CL (L/h/kg) 0.524 - - - - 
Vss (L/kg) 0.291 - - - - 
Cmax (µg/mL) - 0.61 1.4 1.7 4.0 
AUC (mg.h/L) 0.964 5.4 16.5 12.3 29.6 
Oral Bioavailability 
(% F) 
N/A 28.0 17.1 63.8 30.7 
*These two studies were dosed with prodrug 46 orally, and measured for the parent 42a in 
plasma.  
Initial findings with both the 10 mg/kg and 50 mg/kg dose of pro-drug demonstrated a significant 
increase in overall exposure as indicated by a significantly increased AUC, Cmax accompanied 
with increased bioavailability.   
Metabolite ID work was undertaken to establish the metabolic activity exerted upon 46 (Figure 8 
and Table 17). 
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Figure 8. Metabolic pathways of pro-drug 46 in SD rat urine and bile. 
Table 17. Identified metabolites of pro-drug 46 in SD rat urine and bile (MS) 
Peak 
ID 
Mass 
Shift 
Found 
m/z 
Biotransformation R.T(min) Relative MS 
Abundance 
Bile Urine 
46 0 419 Parent 14.3 ND 1.85E+07 
M1 -10 409 Hydrolysis/ 
Hydroxylation 
8.6 5.89E+06 ND 
M2 -10 409 Hydrolysis/ 
Hydroxylation 
9.2 4.21E+06 ND 
M3 -10 409 Hydrolysis/ 
Hydroxylation 
9.9 5.92E+07 2.61E+07 
M4 -26 393 Hydrolysis/ 
Hydroxylation 
10.1 2.12E+07 3.80E+06 
M5 -
42a 
-42 377 Hydrolysis 11.4 5.36E+06 6.12E+06 
 
In the study, five metabolites were detected in the urine and bile of SD rats dosed with 46. These 
metabolites were named as M1 through to M5 based on their eluting time under HPLC conditions. 
Among the five metabolites, M1, M2 and M3 were identified as di-hydroxy 42a; M4 was identified 
as hydroxylated 42a; M5 was identified as active drug 42a. Location of the hydroxyl groups was 
established through mass spectrometry fragmentation patterns (see supporting information). M3 
to M5 were detected both in urine and bile samples, M1 and M2 were only detected in the bile 
sample. 
The presence of the pro-drug in the rat urine indicates that that the pro-drug does not completely 
break down to its active metabolites as predicted. As the plasma levels obtained are a measure of 
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parent drug only, they are not a true representation of the drug levels present. Studies are currently 
underway to establish if a more suitable pro-drug can be synthesised that will resolve the issue and 
provide a compound suitable for in vivo efficacy testing. 
CONCLUSIONS 
To conclude, a 3-6 step synthesis of a range of 2-mono aryl amine 3-methyl quinolones with potent 
anti-tuberculosis activity has been reported. Compounds have been developed that are 
metabolically stable and have a good pharmacokinetic and toxicological profile. Importantly, the 
lead compound 42a demonstrates equipotent activity against all drug sensitive and multi-drug 
resistant strains of Mtb tested. Work continues to develop a suitable pro-drug to embark on in vivo 
efficacy studies. 
EXPERIMENTAL SECTION 
Chemistry 
All reactions that employed moisture sensitive reagents were performed in dry solvent under an 
atmosphere of nitrogen in oven dried glassware. All reagents were purchased from Sigma Aldrich 
or Alfa Aesar chemical companies, and were used without purification. Thin layer chromatography 
(TLC) was carried out on Merck silica gel 60 F-254 plates and U.V. inactive compounds were 
visualised using iodine or anisaldehyde solution. Flash column chromatography was performed on 
ICN Ecochrom 60 (32-63 mesh) silica gel eluting with various solvent mixtures and using an air 
line to apply pressure. NMR spectra were recorded on a Brucker AMX 400 (1 H, 400 MHz; 13C, 
100 MHz) spectrometer. Chemical shifts are described on parts per million () downfield from an 
internal standard of trimethylsilane. Mass spectra were recorded on a VG analytical 7070E 
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machine and Fisons TRIO spectrometers using electron ionisation (EI) and chemical ionisation 
(CI). The optical rotation of the products were determined on Perkin Elmer Polarimeter (Model: 
343Plus), and data was collected and processed by Expert Read 1.00.02 software. All compounds 
were found to be >95% pure by HPLC unless specified below. See supporting information for 
experimental methods and data relating to all intermediates. 
Purity determination was performed by HPLC analysis using Agilent 1200 solvent delivery 
system. The HPLC methods used the following conditions: Knauer Eurospher 100-5 C18(250 mm 
X 4.6 mm) at 25oC with 1.5 mL/min flow rate; Method A: 90% acetonitrile containing 0.05% 
trifluoroacetic acid  and 10% water containing 0.05% trifluoroacetic acid; Method B: 80% 
methanol and 20% acetonitrile. 
 
General procedure for the preparation quinolones 1, 2, 7a-k, 17a-l, 21a-g, 24, 32a-g, 38a-j, 
42a-b and 45a-g. Trifluoromethanesulfonic acid (26 µL, 0.31 mmol, 0.2 eq) was added to 
oxazoline 4 (1.54 mmol) and the respective ketone (1.54 mmol, 1eq) in anhydrous n-butanol (10 
mL). The mixture was heated to 130oC for 24 h (followed by tlc). The reaction was cooled and the 
solvent removed under reduced pressure. Sat. NaHCO3 (aq) was added and the resulting aqueous 
solution was extracted with ethyl acetate (x 3), the combined organic layers were washed with 
water and brine, dried over MgSO4, filtered and concentrated to a yellow solid. The crude product 
was triturated with diethyl ether to give the desired quinolone. In cases where trituration was not 
possible compounds were purified by flash column chromatography. 
Preparation of 3-methyl-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 1. Light yellow powder 
(Yield 23%); m.p 290-292 oC; 1H NMR (400MHz, CDCl3), δH 8.46 (s, 1H, NH), 8.35 (d, 1H, J = 
8.1 Hz, Ar), 7.59-7.52 (m, 1H, Ar), 7.36 (d, 2H, J = 8.7 Hz, Ar), 7.30 (dd, 2H, J = 15.1 H, 7.2 Hz, 
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Ar), 6.96 (d, 2H, J = 8.7 Hz, Ar), 2.10 (3H.CH3), 1.78-1.61 (m, 10H, CH2);  
13C NMR (100MHz, 
CDCl3), δC 179.1, 152.9, 148.0, 139.4, 131.8, 129.9, 126.7, 125.5, 124.0, 123.5, 117.4, 116.5, 
115.6, 50.0, 26.0, 13.0; MS (ES+), [M + H] + (100), 319.2, HRMS calculated for 319.1810 
C21H23N2O, found 319.1808; Anal. C21H22N2O requires C 79.21%, H 6.96%, N 8.80%, found C 
78.83%, H 6.85%, N 8.42%. 
Preparation of 7-methoxy-3-methyl-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 2. Orange 
powder (Yield 36%); m.p 278-280 oC; 1H NMR (400MHz, CDCl3), δH 10.09 (s, 1H, NH), 8.16 (d, 
1H, J = 8.5 Hz, Ar), 7.39 (d, 2H, J 0 8.9 Hz, Ar), 7.10 (d, 2H, J = 8.9 Hz, Ar), 6.92 (dd, 2H, J = 
8.5 Hz, 2.6 Hz, Ar), 3.89 (s, 3H, OCH3), 3.33-3.28 (m, 2H, CH2), 2.06 (s, 3H, CH3), 1.80-1.61 (m, 
6H, CH2); 
13C NMR (100MHz, CDCl3), δC 176.4, 161.8, 152.8, 129.5, 126.5, 124.7, 115.3, 114.7, 
114.3, 97.7, 54.7, 25.3, 24.1, 11.4; MS (ES+), [M + H] + (100), 348.2, HRMS calculated for 
348.1916 C22H25N3O, found 348.2002; Anal. C22H24N2O2 requires C 75.83%, H 6.94%, N 8.04%, 
found C 75.47%, H 6.83%, N 7.61%. 
Preparation of 6-fluoro-3-methyl-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 7a. Orange 
powder (Yield 26%); m.p 328-330 oC 1H NMR (400MHz, DMSO), δH 11.53 (s, 1H, NH), 7.71 
(ddd, 1H, J = 13.9 Hz, 9.3 Hz, 3.9 Hz, Ar), 7.51 (ddd, 1H, J 9.1 Hz, 8.4 Hz, 3.0 Hz, Ar), 7.38 (d, 
2H, J = 8.9 Hz, Ar), 7.07 (d, 2H, J = 8.9 Hz, Ar), 3.30-3.26 (m, 4H, CH2), 1.95 (s, 3H, CH3), 1.66-
1.55 (m, 6H, CH2); 
13C NMR (100MHz, DMSO), δC 176.2, 157.1, 152.2, 148.6, 136.6, 130.2, 
124.3, 121.2, 120.4, 115.0, 113.9,109.1, 49.1, 25.3, 24.3, 12.8; MS (ES+), [M + H] + (100), 337.2, 
HRMS calculated for 337.1716 C21H22N2OF, found 337.1728; Anal. C21H21N2OF requires C 
74.98%, H 6.29%, N 8.33%, found C 74.51%, H 6.07%, N 8.04%. 
Preparation of 6,7-dimethoxy-3-methyl-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 7b. Very 
pale yellow solid (Yield 28%); 1H NMR (400 MHz, DMSO) δH 11.24 (s, 1H, NH), 7.45 (s, 1H, 
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Ar), 7.36 (d, J = 8.8 Hz, 2H, Ar), 7.16 – 6.98 (m, 3H, Ar), 3.83 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 
3.29 – 3.25 (m, 4H, CH2), 1.93 (s, 3H, CH3), 1.69 – 1.53 (m, 6H, CH2); 13C NMR (101 MHz, 
DMSO) δC 175.90 (C=O), 152.89, 152.05, 146.82, 146.54, 135.51, 130.19, 124.73, 117.34, 
114.98, 113.15, 104.50, 99.38, 55.86 (OCH3), 55.79 (OCH3), 49.20, 25.35, 24.32, 12.86 (CH3); 
HRMS (ESI) C23H27N2O3 [M+H]
+ requires 379.2022, found 379.2012 (100%); Anal. C23H26N2O3 
requires C 72.99%, H 6.92%, N 7.40%, found C 71.98%, H 6.96%, N 6.96%. 
Preparation of 6-chloro-7-methoxy-3-methyl-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 7c. 
White solid (Yield 35%); m.p. >300oC. 1H NMR (400 MHz, DMSO) δH 11.42 (s, 1H, NH), 8.02 
(s, 1H, Ar), 7.38 (d, J = 8.8 Hz, 2H, Ar), 7.21 (s, 1H, Ar), 7.07 (d, J = 8.9 Hz, 2H, Ar), 3.91 (s, 
3H, OCH3), 3.31 – 3.22 (m, 4H, CH2), 1.93 (s, 3H, CH3), 1.71 – 1.52 (m, 6H, CH2); 13C NMR 
(101 MHz, DMSO) δC 175.63 (C=O), 156.74, 152.17, 148.16, 140.13, 130.21, 126.09, 124.18, 
118.08, 117.91, 114.89, 114.25, 100.13, 56.59 (OCH3), 49.10, 25.32, 24.32, 12.70 (CH3); HRMS 
(ESI) C22H24N2O2
35Cl [M+H]+ requires 383.1526, found 383.1513 (100%), C22H24N2O2
37Cl 
[M+H]+ requires 385.1497, found 385.1501 (34%). Anal. C22H23N2O2Cl requires C 69.01%, H 
6.05%, N 7.32%, found C 68.98%, H 6.04%, N 7.23%. 
Preparation of 6-fluoro-7-methoxy-3-methyl-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 7d. 
White solid (Yield 41%) 1H NMR (400 MHz, DMSO) δH 11.39 (s, 1H, NH), 7.71 (d, J = 11.9 Hz, 
1H, Ar), 7.37 (d, J = 8.7 Hz, 2H, Ar), 7.24 (d, J = 7.5 Hz, 1H, Ar), 7.07 (d, J = 8.8 Hz, 2H, Ar), 
3.90 (s, 3H, OCH3), 3.30 – 3.19 (m, 4H, CH2), 1.92 (s, 3H, CH3), 1.74 – 1.48 (m, 6H, CH2); 13C 
NMR (101 MHz, DMSO) δC 175.94 (C=O), 152.15, 151.00, 150.87, 150.35, 147.88, 137.55, 
130.20, 124.30, 114.93, 113.57, 110.03, 101.12, 56.36 (OCH3), 49.13, 25.33, 24.32, 12.70 (CH3); 
HRMS (ESI) C22H24N2O2F [M+H]
+ requires 367.1822, found 367.1818. Anal. C22H23N2O2F 
requires C 72.11%, H 6.33%, N 7.64%, found C 71.95%, H 6.45%, N 7.37%. 
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Preparation of 5,7-dimethoxy-3-methyl-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 7e. White 
solid (Yield 32%); m.p. 264 – 265oC. 1H NMR (400 MHz, DMSO) δH 10.93 (s, 1H, NH), 7.33 (d, 
J = 8.7 Hz, 2H, Ar), 7.05 (d, J = 8.7 Hz, 2H, Ar), 6.64 (d, J = 2.2 Hz, 1H, Ar), 6.25 (d, J = 2.1 Hz, 
1H, Ar), 3.78 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.32 – 3.11 (m, 4H, CH2), 1.82 (s, 3H, CH3), 
1.70 – 1.48 (m, 6H, CH2); 13C NMR (101 MHz, DMSO) δC 176.49 (C=O), 161.75, 161.03, 152.02, 
145.53, 143.94, 130.15, 124.47, 115.49, 114.98, 109.24, 94.23, 91.57, 55.97 (OCH3), 55.48 
(OCH3), 49.22, 25.35, 24.32, 12.82 (CH3); HRMS (ESI) C23H27N2O2 [M+H]
+ requires 379.2022, 
found 379.2007. Anal. C23H26N2O2 requires C 72.99%, H 6.92%, N 7.40%, found C 72.13%, H 
6.88%, N 7.03%.  
Preparation of 5,7-difluoro-3-methyl-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 7f. Off 
white solid (0.25 g, 35 %); mp 305-306 °C; 1H NMR (400 MHz, DMSO) δ 11.50 (bs, 1H), 7.37 
(d, J = 8.8 Hz, 2H), 7.15 (d, J = 9.2 Hz, 1H), 7.08 (d, J = 8.9 Hz, 2H), 6.98 (t, J = 9.6 Hz, 1H), 
3.30 (m, 4H), 1.88 (s, 3H), 1.61 (m, 6H); 13C NMR (100 MHz, CDCl3) δC 175.2, 152.1, 148.6, 
130.2, 116.1, 114.9, 100.2, 49.2, 25.3, 24.3, 12.6; MS (ES+) m/z 355 (M + H)+ HRMS calculated 
for 355.1622 C21H21N2OF2, found 355.1625; Purity HPLC 95% (method A) Rt = 2.34 min. 
Preparation of 7-fluoro-3-methyl-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 7g. Off white 
solid (0.15 g, 35 % ); mp 343-345 °C; 1H NMR (400 MHz, DMSO) dd, J = 9.0, 6.6 Hz, 
1H), 7.38 (d, J = 8.8 Hz, 2H), 7.30 (dd, J = 10.5, 2.3 Hz, 1H), 7.10 (m, 1H), 7.05 (d, J = 8.8 Hz, 
2H), 3.28 (m, 4H), 1.94 (s, 3H), 1.62 (m, 6H); 13C NMR (100 MHz, DMSO) C not soluble in 
DMSO; MS (ES+) m/z 337 (M + H)+ HRMS calculated for 337.1716 C21H22N2OF, found 337.1722; 
Purity HPLC 97% (Method B) Rt = 2.44 min. 
Preparation of 7-chloro-3-methyl-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 7h. Off white 
solid (0.17 g, 37 %); mp 342-343 °C; 1H NMR (400 MHz, DMSO) δ 8.08 (d, J = 8.7 Hz, 1H), 7.59 
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(s, 1H), 7.40 ( d, J = 8.8 Hz, 2H), 7.18 (dd, J = 8.7, 2.0 Hz, 1H), 7.04 (d, J  = 8.8 Hz, 2H), 3.08 
(m, 4H), 1.95 (s, 3H), 1.61 (m, 6H); 13C NMR (100 MHz, CDCl3) δC not soluble in DMSO; MS 
(ES+) m/z 353 (M + H)+ HRMS calculated for 353.1425 C21H22N2O
35Cl, found 353.1421; Purity 
HPLC 97% (Method A) Rt = 2.07 min. 
Preparation of 2-(4-(4-fluoropiperidin-1-yl)phenyl)-3-methylquinolin-4(1H)-one 7i. White solid 
(0.18 g, 36 %). 1H NMR (400 MHz, DMSO) 8.10 (d, J = 8.8 Hz, 1H), 7.57 (m, 2H), 7.40 (d, J = 
8.8 Hz, 2H), 7.24 (dd, J = 7.2, 6.8 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 4.88 (d, J = 48.8 Hz, 1H), 
3.24 (m, 4H), 2.03 (m, 2H), 1.95 (s, 3H), 1.80 (m, 2H); 13C NMR (100 MHz, DMSO) C 176.4, 
150.7, 130.6, 130.0, 124.9, 123.3, 122.1, 119.0, 114.8, 113.8, 89.4, 87.8, 44.6, 44.5, 30.5, 30.3, 
12.6; MS (ES+) m/z 337 (M + H)+ HRMS calculated for 337.1716 C21H22N2OF, found 337.1720; 
Purity HPLC 96% (Method A) Rt = 2.21 min.    
Preparation of 2-(4-(4-fluoropiperidin-1-yl)phenyl)-7-methoxy-3-methylquinolin-4(1H)-one 7j. 
Yellow solid (Yield 43%) 1H NMR (400 MHz, DMSO) δ 11.26 (s, 1H, NH), 8.00 (d, J = 8.9 Hz, 
1H, Ar), 7.39 (d, J = 8.6 Hz, 2H, Ar), 7.12 (d, J = 8.6 Hz, 2H, Ar), 7.05 (d, J = 2.1 Hz, 1H, Ar), 
6.88 (dd, J = 8.9, 2.2 Hz, 1H, Ar), 5.02 – 4.77 (m, 1H, CH), 3.82 (s, 3H, OCH3), 3.57 – 3.44 (m, 
2H, CH2), 3.32 – 3.20 (m, 2H, CH2), 2.13 – 1.95 (m, 2H, CH2), 1.91 (s, 3H, CH3), 1.86 – 1.71 (m, 
2H, CH2); 
13C NMR (101 MHz, DMSO) δ 176.78 (C=O), 161.89, 151.28, 147.80, 141.66, 130.39, 
127.22, 125.12, 117.98, 115.22, 114.02, 113.14, 99.23, 89.01 (d, J = 169.4 Hz, C-F), 55.74, 44.87 
(d, J = 6.8 Hz), 30.84 (d, J = 19.0 Hz), 12.78 (CH3); HRMS (ESI) C22H24N2O2F [M+H]
+ requires 
367.1822, found 367.1836. Anal. C22H23N2O2F requires C 72.11%, H 6.33%, N 7.64%, found C 
71.32%, H 6.34%, N 7.46%. 
Preparation of 5,7-difluoro-2-(4-(4-fluoropiperidin-1-yl)phenyl)-3-methylquinolin-4(1H)-one 7k. 
White solid (29%); m.p > 320 °C. 1H NMR (400 MHz, DMSO) 11.51 (s, 1H), 7.40 (m, 2H), 7.15 
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(m, 3H), 7.00 (m, 1H), 3.49 (m, 2H), 3.24 (m, 2H), 2.0 (m, 2H), 1.89 (s, 3H), 1.75 (m, 2H); 13C 
NMR (100 MHz, DMSO) C not soluble in DMSO; MS (ES+) m/z 373 (M + H)+ HRMS calculated 
for 373.1519 C21H20N2OF3, found 373.7528; Purity HPLC 97% (Method A) Rt = 2.18 min.    
General procedure for the preparation of compounds 14a-c. To a solution of ketone 13 (0.24 
mmol) in anhydrous 1,4-dioxane (8 ml) was added ground sodium hydroxide (30 mg, 0.75 mmol, 
3 equiv). The mixture was allowed to reflux at 110oC for 5 h. The solution was cooled to room 
temperature and acidified by addition of 2N hydrochloric acid. The solid was filtered and washed 
with water, followed by ethyl acetate and dried.  
Preparation of 2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 14a. White solid (0.25 g, 70 %). 
m.p. 350 °C;  1H NMR (400 MHz, DMSO) 11.42 (bs, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.76 (d, J = 
8.3 Hz, 1H), 7.71 (d, J = 8.6 Hz, 2H), 7.64 (dd, J = 8.3, 7.0 Hz, 1H), 7.30 (dd, J = 8.3, 7.0 Hz, 1H), 
7.07 (d, J = 8.8 Hz, 2H), 6.29 (s, 1H), 3.33 (m, 4H), 1.19 (m, 6H); 13C NMR (100 MHz, DMSO) 
C  not soluble in DMSO; MS (ES+) m/z 305 (M + H)+ HRMS calculated for 305.1654 C20H21N2O, 
found 305.1662; Anal. C20H20N2O requires C 78.92%, H 6.62%, N 9.20%, found C 78.67%, H 
6.55%, N 8.89%.      
Preparation of 7-methoxy-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 14b. White solid 
(0.065 g, 41 %). m.p. 350 °C;  1H NMR (400 MHz, DMSO) 11.30 (bs, 1H), 7.96 (d, J = 8.9 Hz, 
1H), 7.69 (d, J = 8.7 Hz, 2H), 7.23 (d, J = 2.3 Hz, 1H), 7.07 (d, J = 8.9 Hz, 2H), 6.89 (dd, J = 8.0, 
4.0 Hz, 1H), 6.21 (s, 1H), 3.86 (s, 3H), 3.34 (m, 4H), 1.60 (m, 6H); 13C NMR (100 MHz, DMSO) 
C  not soluble in DMSO; MS (ES+) m/z 335 (M + H)+ HRMS calculated for 335.1760 C21H23N2O2, 
found 335.1761; Purity HPLC 96% (method A) Rt = 1.81 min.  
Preparation of 2-(4-(4-fluoropiperidin-1-yl)phenyl)-7-methoxyquinolin-4(1H)-one 14c. Yellow 
solid (Yield 68%). 1H NMR (400 MHz, DMSO) δH 13.70 (s, 1H, NH), 8.18 (d, J = 9.2 Hz, 1H, 
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Ar), 7.88 (d, J = 9.0 Hz, 2H, Ar), 7.58 (d, J = 2.3 Hz, 1H, Ar), 7.34 (dd, J = 9.2, 2.4 Hz, 1H, Ar), 
7.31 – 7.19 (m, 3H, Ar), 4.93 (dtt, J = 48.9, 7.0, 3.4 Hz, 1H, CH), 3.98 (s, 3H, OCH3), 3.71 – 3.58 
(m, 2H, CH2), 3.51 – 3.37 (m, 2H, CH2), 2.10 – 1.88 (m, 2H, CH2), 1.87 – 1.68 (m, 2H, CH2); 
HRMS (ESI) C21H22N2O2F [M+H]+ requires 353.1665, found 353.1667; Anal. C21H21N2O2F 
requires C 71.57%, H 6.01%, N 7.95%, found C 71.12%, H 5.93%, N 7.71%. 
General procedure for the preparation of compounds 15a-d. Quinolone 14 (0.33 mmol) was 
added to MeOH (20 mL), 2M NaOH (4 mL) and water (4 mL). Sodium dichloroisocyanurate (36 
mgs, 0.17 mmol, 0.5 eq) was added at room temperature and the resultant light orange solution 
was allowed to stir overnight. The solvent was removed in vacuo and the residue was dissolved in 
EtOAc (100 mL), followed by washing with water (50 mL) and brine (50 mL). The crude product 
was purified by column chromatography (eluting with 100 % EtOAc) to afford the desired product. 
Preparation of 3-chloro-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 15a. White solid (40 
mgs, 40 % ); 1H NMR (400 MHz, DMSO)  12.01 (bs, 1H), 8.15 (d, J = 7.9 Hz, 1H), 7.69 (m 2H), 
7.52 (d, J = 8.7 Hz, 2H), 7.38 (m, 1H), 7.09 (d, J = 8.8 Hz, 2H), 3.33 (m, 4H), 1.61 (m, 6H); 13C 
NMR (100 MHz, DMSO) C  171.7, 152.5, 148.7, 139.3, 132.2, 130.7, 125.4, 124.0, 123.8, 122.1, 
118.9, 114.5, 113.2, 48.9, 25.3, 24.3; MS (ES+) m/z 339 (M + H)+ HRMS calculated for 339.1264 
C20H20N2O
35Cl, found 339.1252; Purity HPLC 98% (method A) Rt =  2.13 min.      
Preparation of 3-chloro-7-methoxy-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 15b. White 
solid (27 mgs, 61 % ); 1H NMR (400 MHz, DMSO)  11.82 (bs, 1H), 8.04 (d, J = 9.0 Hz, 1H), 
7.52 (d, J = 8.8 Hz, 2H), 7.11 (m, 3H), 6.99 (dd, J = 9.2, 2.4 Hz, 1H), 3.85 (s, 3H), 3.33 (m, 4H), 
1.61 (m, 6H); 13C NMR (100 MHz, DMSO) C  162.3, 148.1, 141.1, 130.6, 127.3, 118.2, 114.7, 
114.2, 112.9, 99.7, 55.8, 49.1, 25.2, 24.2; MS (ES+) m/z 369 (M + H)+ HRMS calculated for 
369.1370 C21H22N2O2
35Cl, found 369.1375; Purity HPLC 99% (method A) Rt = 1.83 min. 
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Preparation of 3-chloro-2-(4-(4-fluoropiperidin-1-yl)phenyl)-7-methoxyquinolin-4(1H)-one 15c. 
Yellow solid (Yield 52%). MP 304 – 306oC. 1H NMR (400 MHz, DMSO) δH 11.86 (s, 1H, NH), 
8.03 (d, J = 9.0 Hz, 1H, Ar), 7.52 (d, J = 8.8 Hz, 2H, Ar), 7.14 (d, J = 8.9 Hz, 2H, Ar), 7.10 (d, J 
= 2.3 Hz, 1H, Ar), 6.98 (dd, J = 9.0, 2.4 Hz, 1H, Ar), 4.90 (dtt, J = 21.4, 7.3, 3.6 Hz, 1H, CH), 
3.84 (s, 3H, OCH3), 3.63 – 3.46 (m, 2H), 3.34 – 3.19 (m, 2H), 2.13 – 1.90 (m, 2H), 1.85 – 1.58 
(m, 2H); 13C NMR (101 MHz, DMSO) δC 171.31 (C=O), 162.33 (C-O), 151.61, 148.08, 141.06, 
130.67, 127.30, 122.71, 118.20, 114.66, 114.20, 112.89, 99.63, 88.89 (d, J = 169.5 Hz, C-F), 55.81, 
44.53 (d, J = 6.8 Hz), 30.69 (d, J = 19.1 Hz); HRMS (ESI) C21H21N2O2F
35Cl [M+H]
+ requires 
387.1276, found 387.1287. Anal. C21H20N2O2FCl requires C 65.20%, H 5.21%, N 7.24%, found 
C 64.90%, H 5.35%, N 6.95%. 
Preparation of 3-chloro-2-(4-(4-fluoropiperidin-1-yl)phenyl)quinolin-4(1H)-one 15d. Light 
yellow solid (0.19 g, 58 %).  1H NMR (400 MHz, DMSO) 12.05 (bs, 1H), 8.15 (d, J = 8.0 Hz, 1H), 
7.70 (d, J = 4.0 Hz, 2H), 7.54 (d, J = 8.8 Hz, 2H), 7.38 (m, 1H), 7.15 (d, J = 8.8 Hz, 2H), 4.89 (d, 
J = 48.0 Hz, 1H), 3.53 (m, 2H), 3.30 (m, 2H), 1.97 (m, 2H), 1.79 (m, 2H); 13C NMR (100 MHz, 
DMSO) C 175.2, 150.8, 128.5, 127.9, 127.3, 124.6, 115.4, 103.9, 89.9, 88.2, 79.6, 66.7, 45.2, 
45.1, 31.0, 30.8, 15.5; MS (ES+) m/z 357 (M + H)+ HRMS calculated for 357.1170 
C20H19N2OF
35Cl, found 357.1159; Purity HPLC 95% (Method A) Rt = 2.15 min. 
General procedure for the preparation of compounds 15e-f. Quinolone 14 (0.33 mmol) was 
added to DCM (15 mL) and MeOH (4 mL). NBS (58 mgs, 0.33 mmol) was added at room 
temperature and the resultant bright yellow solution was allowed to stir overnight. The solvent was 
removed in vacuo and the residue was dissolved in EtOAc (100 mL), followed by washing with 
water (50 mL) and brine (50 mL). The crude product was purified by column chromatography 
(eluting with 70 % EtOAc in n-hexanes) to afford the desired product.  
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Preparation of 3-bromo-2-(4-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 15e. White solid (63 %); 
1H NMR (400 MHz, DMSO)  12.07 (bs, 1H), 8.15 (d, J = 8.1 Hz, 1H), 7.68 (m 2H), 7.49 (d, J = 
8.8 Hz, 2H), 7.39 (ddd, J = 8.6, 7.9, 4.1 Hz, 1H), 7.08 (d, J = 8.8 Hz, 2H), 3.31 (m, 4H), 1.62 (m, 
6H); 13C NMR (100 MHz, DMSO) C  172.1, 152.5, 150.4, 139.4, 132.3, 130.6, 125.6, 124.2, 
124.0, 123.2, 118.8, 114.5, 105.5, 49.0, 25.3, 24.4; MS (ES+) m/z 383 (M + H)+ HRMS calculated 
for 383.0759 C20H20N2O
79Br, found 383.0748; Purity HPLC 98% (Method A) Rt = 1.75 min.      
Preparation of 3-bromo-2-(4-(4-fluoropiperidin-1-yl)phenyl)quinolin-4(1H)-one 15f. Light 
yellow solid (0.20g, 55 %).  1H NMR (400 MHz, DMSO) 12.26 (bs, 1H), 8.15 (d, J = 8.8 Hz, 1H), 
7.69 (m, 1H), 7.50 (d, J = 8.8 Hz, 2H), 7.39 (m, 2H), 7.14 (d, J = 8.8 Hz, 2H), 4.89 (d, J = 48.0 
Hz, 1H), 3.53 (m, 2H), 3.30 (m, 2H), 1.97 (m, 2H), 1.79 (m, 2H) . 13C NMR (100 MHz, DMSO) 
C 179.7, 150.3, 132.3, 130.2, 125.6, 124.5, 114.6, 105.6, 89.7, 88.1, 44.6, 44.5, 30.8, 15.5; MS 
(ES+) m/z 401 (M + H)+ HRMS calculated for 401.0665 C20H19N2OF
79Br, found 401.0656; Purity 
HPLC 99% (Method A) Rt = 2.15 min. 
Preparation of 5,7-difluoro-3-methyl-2-(4-(4-(trifluoromethyl)piperidin-1-yl)phenyl)quinolin-
4(1H)-one 17a. White solid (32%); m.p. >350 °C. 1H NMR (400 MHz, DMSO) 11.52 (s, 1H), 
7.39 (m, 2H), 7.17 (m, 3H), 7.00 (m, 1H), 3.95 (m, 2H), 2.85 (m, 2H), 1.91 (m, 2H), 1.87 (s, 3H), 
1.55 (m, 2H); 13C NMR (100 MHz, DMSO) C not soluble in DMSO; MS (ES+) m/z 423 (M + H)+ 
HRMS calculated for 423.1496 C22H20N2OF5, found 423.1483; Anal. C22H19N2OF5 requires C 
62.56%, H 4.53%, N 6.63%, found C 62.49%, H 4.52%, N 6.62%.   
Preparation of 5,7-difluoro-3-methyl-2-(4-(4-methylpiperidin-1-yl)phenyl)quinolin-4(1H)-one 
17b. White solid (54%); m.p. decomposed at 310°C. NMR: 1H (400 MHz, DMSO) δ 11.50 (s, 1H), 
7.36 (d, J = 8.8 Hz, 2H), 7.16 (d, J = 10.0 Hz, 1H), 7.08 (d, J = 8.9 Hz, 2H), 7.00 (ddd, J = 12.0, 
9.6, 2.4 Hz, 1H), 3.83 (d, J = 12.8 Hz, 2H), 2.76 (td, J = 12.5, 2.4 Hz, 2H), 1.87 (s, 3H), 1.70 (d, J 
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= 12.7 Hz, 2H), 1.63 – 1.49 (m, 1H), 1.21 (qd, J = 12.7, 4.0 Hz, 2H), 0.94 (d, J = 6.5 Hz, 3H); 13C 
(101 MHz, DMSO) δ 175.37, 163.51, 160.76, 152.01, 147.65, 142.84, 130.21, 123.60, 116.33, 
114.91, 110.49, 99.41, 98.81, 48.41, 33.55, 30.65, 22.18, 12.51. ES HRMS: m/z found 369.1792, 
C22H23N2OF2 requires 369.1778; Anal. C22H22N2OF2 requires C 71.72%, H 6.02%, N 7.60%, 
found C 71.66%, H 5.95%, N 7.52%. 
Preparation of 2-(4-(6-azaspiro[2.5]octan-6-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-one 
17c. White solid (Yield 34%); m.p. > 300oC. 1H NMR (400 MHz, DMSO) δH 11.51 (s, 1H, NH), 
7.38 (d, J = 8.7 Hz, 2H), 7.16 (d, J = 10.0 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 7.00 (ddd, J = 11.9, 
9.6, 2.3 Hz, 1H), 3.38 – 3.35 (m, 4H), 1.88 (s, 3H, CH3), 1.53 – 1.36 (m, 4H), 0.35 (s, 4H); 13C 
NMR (101 MHz, DMSO) δ 175.52, 163.75 (d, J = 61.6 Hz), 161.38 (d, J = 77.0 Hz), 152.14, 
147.75, 142.80 (dd, J = 14.7, 6.3 Hz), 130.34, 123.72, 116.45, 115.22, 110.59 (d, J = 2.4 Hz), 
99.60 (dd, J = 24.9, 4.1 Hz), 98.95 (dd, J = 28.7, 25.6 Hz), 48.40, 34.32, 18.15, 12.61, 11.59. 
HRMS (ESI) C23H22N2OF
23Na [M+Na]
+ requires 403.1598, found 403.1612. Anal. C23H22N2OF 
requires C 72.61%, H 5.83%, N 7.36%, found C 72.41%, H 5.91%, N 7.31%. 
Preparation of 2-(4-(4,4-difluoropiperidin-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-one 
17d. White solid (0.30 g, 57 %).  1H NMR (400 MHz, DMSO) 7.38 (d, J = 8.8 Hz, 2H), 7.10 (d, J 
= 8.8 Hz, 2H), 7.07 (m, 1H), 6.82 (dd, J = 11.0, 10.6 Hz, 1H), 3.43 (m, 4H), 2.07 (m, 4H), 1.88 (s, 
3H); 13C NMR (100 MHz, DMSO) δC 174.2, 149.5, 129.9, 122.8, 118.5, 115.3, 115.0, 45.3, 33.0, 
32.8, 32.5, 12.6; MS (CI+) m/z 391 (M + H)+ HRMS calculated for 391.1428 C21H19N2OF4, found 
391.1430; Purity HPLC 95% (Method A) Rt = 2.39 min.  
Preparation of 5,7-difluoro-2-(4-(3-fluoropiperidin-1-yl)phenyl)-3-methylquinolin-4(1H)-one 
17e. Light brown solid (0.12 g, 27 %).  1H NMR (400 MHz, DMSO) 11.49 (bs, 1H), 7.38 (d, J = 
8.8 Hz, 2H), 7.10 (d, J = 8.8 Hz, 2H), 7.07 (m, 1H), 6.99 (dd, J = 11.0, 10.6 Hz, 1H),4.82 (d, J = 
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48.8 Hz, 1H), 3.50-3.33 (m, 4H), 1.87 (s, 3H), 1.86-1.62 (m, 4H) ; 13C NMR (100 MHz, DMSO) 
C 175.2, 151.4, 147.1, 129.8, 123.6, 116.0, 114.6, 98.8, 88.1, 86.4, 51.8, 51.6, 47.3, 29.3, 29.1, 
20.6, 20.5, 12.1; MS (EI+) m/z 373 (M + H)+ HRMS calculated for 373.1528 C21H20N2OF3, found 
373.1524; Purity HPLC 97% (Method A) Rt = 2.42 min.   
Preparation of 5,7-difluoro-3-methyl-2-(4-(3-methylpiperidin-1-yl)phenyl)quinolin-4(1H)-one 
17f. White solid (45%). Melting point: 280~282°C. NMR: 1H (400 MHz, DMSO) δ 11.50 (s, 1H), 
7.36 (d, J = 8.8 Hz, 2H), 7.16 (d, J = 9.0 Hz, 1H), 7.07 (d, J = 8.9 Hz, 2H), 7.00 (ddd, J = 12.0, 9.6, 
2.4 Hz, 1H), 3.77 (t, J = 11.6 Hz, 2H), 2.72 (td, J = 12.3, 2.9 Hz, 1H), 2.42 (dd, J = 12.4, 10.7 Hz, 
1H), 1.87 (s, 3H), 1.82 – 1.48 (m, 4H), 1.09 (ddd, J = 23.5, 12.4, 3.9 Hz, 1H), 0.93 (d, J = 6.6 Hz, 
3H).13C (101 MHz, DMSO) δ 175.37, 164.10, 161.50, 152.00, 147.66, 142.69, 130.22, 123.46, 
116.33, 114.81, 110.59, 99.40, 98.79, 55.93, 48.45, 32.93, 30.35, 24.72, 19.58, 12.50. ES HRMS: 
m/z found 369.1772, C22H23N2OF2 requires 369.1778; Anal. C22H22N2OF2 requires C 71.72%, H 
6.02%, N 7.60%, found C 71.76%, H 5.94%, N 7.58%. 
Preparation of (R)-5,7-difluoro-3-methyl-2-(4-(3-methylpiperidin-1-yl)phenyl)quinolin-4(1H)-
one 17g. White solid (43%). 1H and 13C NMR data is the same as the racemic analogue; ES HRMS: 
m/z found 369.1775, C22H23N2OF2 requires 369.1778; Anal. C22H22N2OF2 requires C 71.72%, H 
6.02%, N 7.60%, found C 71.68%, H 6.06%, N 7.53%; the optical rotation was measured as 
[α]D22=+81.5°±0.9 (c=0.558g/100ml in MeOH). 
Preparation of (S)-5,7-difluoro-3-methyl-2-(4-(3-methylpiperidin-1-yl)phenyl)quinolin-4(1H)-
one 17h. White solid (40%). 1H and 13C NMR data is the same as the racemic analogue; ES HRMS: 
m/z found 369.1782, C22H23N2OF2 requires 369.1778; Anal. C22H22N2OF2 requires C 71.72%, H 
6.02%, N 7.60%, found C 71.77%, H 6.0%, N 7.64%; the optical rotation was measured as [α]D22=-
86.1°±0.7 (c=0.588g/100ml in MeOH).  
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Preparation of 5,7-difluoro-3-methyl-2-(4-(4-methylpiperazin-1-yl)phenyl)quinolin-4(1H)-one 
17i. White solid (39%); m.p. >350 °C. 1H NMR (400 MHz, DMSO) 11.50 (s, 1H), 7.89 (d, J = 
9.0, 2H), 7.19 (m, 1H), 7.05 (m, 1H), 6.85 (d, J = 9.0, 2H), 3.35 (m, 4H), 2.55 (m, 4H), 2.31 (s, 
3H), 1.90 (s, 3H); 13C NMR (100 MHz, DMSO) C not soluble in DMSO; MS (ES+) m/z 370 (M 
+ H)+ HRMS calculated for 370.1717 C21H22N3OF2, found 370.1731; Purity HPLC 99% (Method 
A) Rt = 1.59 min.  
Preparation of 2-(4-(azepan-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-one 17j. White 
solid (41%); m.p. >350 °C. 1H NMR (400 MHz, DMSO) 11.45 (s, 1H), 7.31 (d, J = 8.8, 2H), 7.19 
(m, 1H), 7.00 (m, 1H), 6.85 (d, J = 8.9, 2H), 3.55 (m, 4H), 1.92 (s, 3H), 1.75 (bs, 4H), 1.45 (bs, 
4H); 13C NMR (100 MHz, DMSO) C 175.4, 149.4, 147.8, 130.5, 120.5, 116.1, 110.8, 99.54, 98.9, 
98.7, 49.1, 48.1, 47.9, 47.7, 47.5, 27.0, 26.6, 12.6; MS (ES+) m/z 369 (M + H)+ HRMS calculated 
for 369.1764 C22H23N2OF2, found 369.1778; Anal. C22H22N2OF2 requires C 71.72%, H 6.02%, N 
7.60%, found C 71.36%, H 5.97%, N 7.39%.    
Preparation of 2-(4-(benzylamino)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-one 17k. White 
solid (51%); m.p. 282-283°C.NMR: 1H (400 MHz, DMSO) δ 11.39 (s, 1H), 7.36 (dt, J = 15.1, 7.4 
Hz, 4H), 7.27 – 7.21 (m, 3H), 7.13 (d, J = 9.0 Hz, 1H), 6.97 (ddd, J = 12.0, 9.8, 2.3 Hz, 1H), 6.84 
(t, J = 6.1 Hz, 1H), 6.72 (d, J = 8.6 Hz, 2H), 4.36 (d, J = 6.1 Hz, 2H), 1.86 (s, 3H); 13C (101 MHz, 
DMSO) δ 175.36, 164.04, 161.44, 150.01, 148.03, 142.58, 141.46, 140.25, 130.20, 128.73, 127.47, 
127.09, 121.61, 116.08, 112.05, 99.34, 98.71, 46.39, 12.56. ES HRMS: m/z found 377.1465, 
C23H19N2OF2 requires 377.1465; Anal. C23H18N2OF2 requires C 73.39%, H 4.82%, N 7.44%, 
found C 73.18%, H 4.74%, N 7.41%. 
Preparation of 2-(4-(dimethylamino)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-one 17l. 
White solid (46%); m.p. 294°C. NMR: 1H (400 MHz, DMSO) δ 11.48 (s, 1H), 7.37 (d, J = 8.8 Hz, 
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2H), 7.17 (d, J = 10.1 Hz, 1H), 6.99 (ddd, J = 12.1, 9.6, 2.4 Hz, 1H), 6.86 (d, J = 8.9 Hz, 2H), 2.99 
(s, 6H), 1.88 (s, 3H); 13C (101 MHz, DMSO) δ 175.39, 164.08, 160.75, 151.31, 147.89, 142.77, 
130.17, 121.70, 116.20, 111.89, 110.45, 99.38, 98.77, 40.24, 12.55. ES HRMS: m/z found 
315.1319, C18H17N2OF2 requires 315.1309; Anal. C18H16N2OF2 requires C 68.78%, H 5.13%, N 
8.91%, found C 68.47%, H 5.14%, N 8.78%. 
Preparation of 2-(4-(4-benzylpiperidin-1-yl)phenyl)-3-methylquinolin-4(1H)-one 21a. White 
powder (Yield 33%); m.p 256-258 oC 1H NMR (400MHz, DMSO), δH 11.39 (s, 1H, NH), 8.10 (d, 
1H, J = 7.7 Hz,  Ar), 7.63-7.55 (m, 2H, AR), 7.37 (d, 2H, J = 8.9 Hz, Ar), 7.33-7.24 (m, 3H, Ar), 
7.22-7.17 (m, 3H, Ar), 706 (d, 2H, J = 8.9 Hz, Ar), 3.82 (d, 2H, J = 12.8 Hz, CH2), 2.79-2.66 (m, 
2H, CH2), 2.56 (d, 2H, J = 7.0 Hz, CH2Ar), 1.96 (s, 3H, CH3), 1.79-1.73 (m, 1H, CH), 1.67 (d, 2H, 
J = 12.9 Hz, CH2), 1.29 (qd, 2H, J = 12.6 Hz, 3.9 Hz, CH2) 
13C NMR (100MHz, DMSO), δC 177.0, 
151.9, 148.3, 140.5, 139.9, 131.3, 130.2, 129.4, 128.5, 126.2, 125.3, 124.5, 123.3, 122.7, 118.4, 
115.0, 114.4, 48.7, 42.6, 37.7, 31.5, 12.8 MS (ES+), [M + H] + (100), 409.2, HRMS calculated for 
409.2280 C28H29N2O, found 409.2289; Anal. C28H28N2O requires C 82.32%, H 6.91%, N 6.86%, 
found C 81.98%, H 6.92%, N 6.88%. 
Preparation of 2-(4-(4-benzylpiperidin-1-yl)phenyl)-6-fluoro-3-methylquinolin-4(1H)-one 21b. 
White powder (Yield 40%); m.p. 302-302 oC 1H NMR (400MHz, DMSO), δH 11.55 (s,1H, NH), 
7.73 (dd, 1H, J = 9.5 Hz, 3.0 Hz, Ar), 7.68 (dd, 1H, J = 9.1 Hz, 4.7 Hz, Ar), 7.54-7.48 (m, 1H, Ar), 
7.38 (d, 2H, J = 8.9 Hz, Ar), 7.33-7.27 (m, 2H, Ar), 7.23-7.17 (m, 3H, Ar), 7.06 (d, 2H, J = 8.9 
Hz, Ar), 3.83 (d, 2H, J = 12.7 Hz, CH2), 2.79-2.67 (m, 2H, CH2), 2.55 (d, 2H, J = 7.0 Hz, CH2Ar), 
1.94 (s, 3H, CH3), 1.80-1.68 (m, 1H, CH), 1.67 (d, 2H, J = 13.1 Hz, CH2), 1.28 (qd, 2H, J = 12.6 
Hz, 3.9 Hz, CH2) 
13C NMR (100MHz, DMSO), δC 176.2, 157.1, 152.0, 148.6, 140.5, 136.6, 130.2, 
129.4, 128.5, 126.2, 124.3, 121.2, 120.4, 115.0, 113.9, 109.1, 48.4, 42.6, 37.7, 31.4, 12.7 MS 
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(ES+), [M + H]+ (100), 427.2, HRMS calculated for 427.2186 C28H28N2O4F, found 427.2177; 
Anal. C28H27N2OF requires C 78.85%, H 6.38%, N 6.57%, found C 78.31%, H 6.35%, N 6.63%. 
Preparation of 2-(4-(4-benzylpiperidin-1-yl)phenyl)-7-methoxy-3-methylquinolin-4(1H)-one 21c. 
Light yellow powder (Yield 42 %); m.p. 218-220 oC 1H NMR (400MHz, DMSO), δH 11.21 (s, s, 
1H, NH), 7.99 (d, 1H, J = 8.9 Hz, Ar), 7.36 (d, 2H, J = 8.7 Hz, Ar), 7.29 (d, 2H, J = 7.2 Hz, Ar), 
7.20 (d, 3H, J = 6.4 Hz, Ar), 7.05 (d, 3H, J = 8.6 Hz, Ar), 6.87 (dd, 1H, J = 8.9 Hz, 2.4 Hz, Ar), 
3.82 (s, 3H, OCH3), 2.71 (t, 2H, J = 11.5 Hz, CH2), 2.56 (d, 2H, J = 6.9 Hz, CH2Ar), 1.91 (s, 3H, 
CH3), 1.79-1.71 (m, 1H, CH), 1.29 (dt, 2H, J = 11.7 Hz, 8.9 Hz, CH2) 
13C NMR (100MHz, DMSO), 
δC 176.7, 161.8, 151.8, 147.8,141.6, 140.5, 130.2, 129.4, 128.5, 127.1, 126.2, 124.6, 117.9, 115.0, 
113.9, 113.0, 99.2, 55.6, 48.5, 42.6, 37.7, 31.5, 12.7 MS (ES+), [M + H] + (100),  439.2 HRMS 
calculated for 439.2386 C29H31N2O2, found 439.2386; Purity HPLC 95% (Method B) Rt = 2.43 
min. 
Preparation of 2-(4-(4-benzylpiperazin-1-yl)phenyl)-3-methylquinolin-4(1H)-one 21d. White 
powder (Yield 30%); m.p. 258-260 oC 1H NMR (400MHz, DMSO), δH 11.40 (s, 1H, NH), 8.10 
(d, 1H, J = 7.7 Hz, AR), 7.63-7.55 (m, 2H, Ar), 7.40 (d, 2H, J = 8.9 Hz, Ar), 7.37-7.33 (m, 3H, 
Ar), 7.27 (ddd, 2H, J = 10.3 Hz, 5.5 Hz, 2.5 Hz, Ar), 7.08 (d, 2H, J = 8.9 Hz, Ar), 3.54 (s, 2H, 
CH2Ar), 3.29-3.23 (m, 4H, NCH2), 2.58-2.52 (m, 4H, CH2N), 1.93 (s, 3H, CH3)  
13C NMR 
(100MHz, DMSO), δC 177.0, 151.9, 148.2, 139.9, 138.4, 131.4, 130.2, 129.3, 128.6, 127.4, 125.3, 
123.3, 122.8, 118.4, 114.9, 114.4, 62.4, 52.8, 49.0, 48.1, 12.7 MS (ES+), [M + H] + (100), 410.2, 
HRMS calculated for 410.2232 C27H28N3O, found 410.2234; Anal. C27H27N3O requires C 79.19%, 
H 6.65%, N 10.26%, found C 78.63%, H 6.66%, N 10.21%. 
Preparation of 2-(4-(4-benzylpiperazin-1-yl)phenyl)-6-fluoro-3-methylquinolin-4(1H)-one 21e. 
White powder (Yield 28%); m.p. 306-308 oC. 1H NMR (400MHz, DMSO), δH 11.69 (s, 1H, NH), 
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7.74-7.71 (m, 2H, Ar), 7.54-7.48 (m, 1H, Ar), 7.40 (d, 2H, J = 8.9 Hz, Ar), 7.37-7.33 (m, 4H, Ar), 
7.08 (d, 2H, J = 8.9 Hz, Ar), 3.54 (s, 2H, CH2Ar), 3.30-3.22 (m, 4H, CH2N), 2.59-2.52 (m, 4H, 
NCH2), 1.94 (s, 3H, CH3)  
13C NMR (100MHz, DMSO), δC 151.9, 148.6, 138.4, 136.7, 130.2, 
129.3, 128.6, 127.4, 124.9, 124.2, 120.4, 114.8, 113.9, 109.0, 62.4, 55.3, 52.8, 48.0, 12.8 MS 
(ES+), [M + H] + (100), 428.2, HRMS calculated for 428.2138 C27H27N3OF, found 428.2138; 
Purity HPLC 98% (Method A) Rt = 1.82 min.. 
Preparation of 7-methoxy-3-methyl-2-(4-(4-phenylpiperazin-1-yl)phenyl)quinolin-4(1H)-one 21f. 
White powder (Yield 30 %); m.p. 312-314 oC. 1H NMR (400MHz, DMSO), δH 11.25 (s, 1H, NH), 
8.01 (d, 1H, J = 9.0 Hz, Ar), 7.43 (d, 2H, J = 8.8 Hz, Ar), 7.26 (dd, 2H, J = 8.4 Hz, Ar), 7.16 (d, 
2H, J = 8.8 Hz, Ar), 7.05 (d, 1H, J = 2.4 Hz, Ar), 7.02 (d, 2H. J = 8.0 Hz, Ar), 6.88 (dd, 1H, J = 
9.0 Hz, Ar), 6.83 (t, 1H, J = 7.3 Hz, Ar), 3.82 (s, 3H, OCH3), 3.41 (dd, 4H, J = 6.5 Hz, 3.5 Hz, 
NCH2), 3.31 (dd, 4H, J = 6.5 Hz, 3.5 Hz, CH2N), 1.92 (s, 3H, CH3) 
13C NMR (100MHz, DMSO), 
δC 176.7, 161.8, 151.7, 151.3, 147.7, 141.6, 130.2, 129.4, 127.1, 125.6, 119.6, 117.9, 116.1, 115.1, 
114.0, 113.0, 99.2, 55.7, 48.6, 48.1, 12.6 MS (ES+), [M + H] + (100), 426.2, HRMS calculated for 
426.2182 C27H28N3O2, found 426.2184; Purity HPLC 91% (Method A) Rt = 1.80 min. 
Preparation of 2-(4-(4-benzylpiperazin-1-yl)phenyl)-7-methoxy-3-methylquinolin-4(1H)-one 21g. 
White powder (Yield 38%); m.p. 280-282 oC. 1H NMR (400MHz, DMSO), δH 11.22 (s, 1H, NH), 
8.00 (d, 1H, J = 9.0 Hz, AR), 7.38 (d, 2H, J = 8.9 Hz, Ar), 7.37-7.33 (m, 4H, Ar), 7.31-7.24 (m, 
1H, Ar), 7.07 (d, 2H, J = 8.9 Hz, Ar), 7.04 (d, 1H, J = 2.4 Hz, Ar), 6.87 (dd, 1H, J = 8.9 Hz, 2.4 
Hz, Ar), 3.82 (s, 3H, OCH3), 3.54 (s, 2H, NCH2Ar), 3.29-3.23 (m, 4H, NCH2), 2.57-2.52 (m, 4H, 
CH2N), 1.91 (s, 3H, CH3)  
13C NMR (100MHz, DMSO), δC 176.7, 161.8, 151.8, 147.7, 141.6, 
138.4, 130.1, 129.3, 128.6, 127.4, 125.3, 117.9, 114.8, 113.0, 99.2, 62.4, 55.6, 52.8, 49.0, 48.0, 
12.6 MS (ES+), [M + H] + (100), 440.2, HRMS calculated for 440.2338 C28H30N3O2, found 
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440.2344; Anal. C28H29N3O2 requires C 76.51%, H 6.65%, N 9.56%, found C 76.12%, H 6.63%, 
N 9.48%. 
Preparation of 5,7-difluoro-3-methyl-2-(3-(piperidin-1-yl)phenyl)quinolin-4(1H)-one 24. White 
solid (Yield 45%); m.p. 269 – 270oC. 1H NMR (400 MHz, DMSO) δH 11.63 (s, 1H, NH), 7.37 (t, 
J = 7.9 Hz, 1H, Ar), 7.16 (d, J = 9.8 Hz, 1H, Ar), 7.10 (dd, J = 8.4, 2.3 Hz, 1H, Ar), 7.06 – 6.97 
(m, 2H, Ar), 6.86 (d, J = 7.5 Hz, 1H, Ar), 3.27 – 3.19 (m, 4H, CH2), 1.83 (s, 3H, CH3), 1.62 (d, J 
= 4.0 Hz, 4H, CH2), 1.59 – 1.50 (m, 2H, CH2); 13C NMR (101 MHz, DMSO) δ 175.48, 163.86 
(dd, J = 65.8, 15.2 Hz), 161.33 (dd, J = 80.6, 14.7 Hz), 151.93, 148.14, 142.72 (dd, J = 14.7, 6.4 
Hz), 135.62, 129.68, 118.86, 116.90, 116.66, 116.07, 110.74 (d, J = 10.7 Hz), 99.66 (dd, J = 24.4, 
4.5 Hz), 99.06 (dd, J = 26.8, 25.8 Hz), 49.65, 25.57, 24.33, 12.44. HRMS (ESI) C21H20N2OF2
23Na 
[M+H]+  requires 377.1441, found 377.1448 (100%). Anal. C21H20N2OF2 requires C 71.17%, H 
5.69%, N 7.90%, found C 70.78%, H 5.59%, N 7.64%. 
Preparation of 1-(4-(5,7-difluoro-3-methyl-4-oxo-1,4-dihydroquinolin-2-yl)phenyl)-1H-pyrrole-
2-carbonitrile 32a. White solid (55%); m.p. 312°C. NMR: 1H (400 MHz, DMSO) δ 11.81 (s, 1H), 
7.84 – 7.74 (m, 4H), 7.67 (dd, J = 2.8, 1.6 Hz, 1H), 7.31 (dd, J = 4.0, 1.6 Hz, 1H), 7.15 (d, J = 10.0 
Hz, 1H), 7.06 (ddd, J = 12.0, 9.6, 2.4 Hz, 1H), 6.52 (dd, J = 3.9, 2.8 Hz, 1H), 1.86 (s, 3H); 13C (101 
MHz, DMSO) δ 175.33, 161.19, 146.24, 142.77, 138.87, 134.57, 130.86, 128.96, 128.22, 124.59, 
123.61, 117.07, 114.20, 111.64, 110.81, 103.09, 99.47, 99.21, 12.25; HRMS (ESI) C21H14N3OF2 
[M+H]+  requires 362.1099, found 362.1108 (100%). Anal. C21H13N3OF2 requires C 69.80%, H 
3.63%, N 11.63%, found C 69.67%, H 3.66%, N 11.38%. 
Preparation of 2-(4-(1H-indol-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-one 32b. while 
solid (57%); m.p. decomposed at 325°C. NMR: 1H (400 MHz, DMSO) δ 11.79 (s, 1H), 7.84 (d, J 
= 8.5 Hz, 2H), 7.81 – 7.74 (m, 3H), 7.69 (t, J = 8.6 Hz, 2H), 7.26 (t, J = 7.7 Hz, 1H), 7.22 – 7.14 
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(m, 2H), 7.06 (ddd, J = 12.0, 9.7, 2.4 Hz, 1H), 6.78 (d, J = 3.3 Hz, 1H), 1.91 (s, 3H); 13C (101 
MHz, DMSO) δ 175.38, 146.64, 142.71, 140.41, 137.96, 135.25, 132.43, 130.93, 129.74, 128.77, 
123.87, 122.96, 121.51, 120.98, 117.40, 117.01, 110.75, 104.64, 99.47, 99.13, 96.43, 12.35; 
HRMS (ESI) C24H17N2OF2 [M+H]
+  requires 387.1303, found 387.1300 (100%). Anal. 
C24H16N2OF2 requires C 74.60%, H 4.17%, N 7.25%, found C 74.21%, H 4.17%, N 7.24%. 
Preparation of 2-(4-(1H-pyrazol-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-one 32c. 
White solid (Yield 35%); m.p. 306oC. 1H NMR (400 MHz, DMSO) δH 11.73 (s, 1H, NH), 8.66 (d, 
J = 2.5 Hz, 1H), 8.07 (d, J = 8.6 Hz, 2H), 7.83 (d, J = 1.6 Hz, 1H), 7.70 (d, J = 8.5 Hz, 2H), 7.16 
(d, J = 9.8 Hz, 1H), 7.05 (ddd, J = 11.9, 9.7, 2.3 Hz, 1H), 6.74 – 6.53 (m, 1H), 1.87 (s, 3H, CH3); 
13C NMR (101 MHz, DMSO) δ 175.47 (C=O), 163.94 (dd, J = 72.7, 14.9 Hz, C-F), 161.40 (dd, J 
= 87.4, 15.3 Hz, C-F), 146.70, 142.81 (dd, J = 14.6, 6.2 Hz), 142.04, 140.83, 132.36, 130.81, 
128.55, 118.62, 117.04, 110.80 (d, J = 8.8 Hz), 108.85, 99.70 (dd, J = 24.4, 4.5 Hz), 99.09 (d, J = 
25.2 Hz), 12.40 (CH3); HRMS (ESI) C19H13N3OF2
23Na [M+Na]
+ requires 360.0924, found 
360.0935. Anal. C19H13N3OF2 requires C 67.65%, H 3.88%, N 12.46%, found C 67.26%, H 4.00%, 
N 12.24%. 
Preparation of 2-(4-(1H-pyrrol-1-yl)phenyl)-5-fluoro-3-methylquinolin-4(1H)-one 32d. White 
solid (Yield 32%); m.p. >300oC. 1H NMR (400 MHz, DMSO) δH 11.66 (s, 1H, NH), 7.96 – 7.73 
(m, 2H), 7.67 – 7.61 (m, 2H), 7.61 – 7.49 (m, 3H), 7.42 (d, J = 8.4 Hz, 1H), 6.97 (dd, J = 12.1, 7.9 
Hz, 1H), 6.49 – 6.14 (m, 2H), 1.88 (s, 3H, CH3); 13C NMR (101 MHz, DMSO) δC 175.85 (C=O), 
162.15, 159.57, 146.57, 142.23, 142.21 (d, J = 4.4 Hz), 140.89, 132.06 (d, J = 10.8 Hz), 131.60, 
130.84, 119.35 (d, J = 12.6 Hz), 116.59, 114.53, 113.36 (d, J = 8.8 Hz), 111.37, 108.68 (d, J = 
20.9 Hz), 12.46 (CH3). HRMS (ESI) C20H15N2OF
23Na [M+Na]
+ requires 341.1066, found 
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341.1080. Anal. C20H15N2OF requires C 75.46%, H 4.75%, N 8.80%, found C 75.23%, H 4.70%, 
N 8.72%. 
Preparation of 2-(4-(3,4-difluoro-1H-pyrrol-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-
one 32e. White solid (38 mgs, 30 %). 1H NMR (400 MHz, DMSO) 11.78 (bs, 1H), 7.83 (d, J = 8.8 
Hz, 2H), 7.72 (d, J = 8.8 Hz, 4H), 7.14 (d, J = 9.6 Hz, 1H), 7.11 (dd, J = 11.0, 10.6 Hz, 1H), 1.91 
(s, 3H), 13 C 175.1, 146.8, 140.3, 131.8, 130.8, 118.7, 116.9, 103.0, 
12.3; MS (ES+) m/z 373 (M + H)+ HRMS calculated for 373.0964 C20H13N2OF4, found 373.0965; 
Purity HPLC 98% (Method A) Rt = 2.29 min.    
Preparation of 2-(3-chloro-4-(1H-pyrrol-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-one 
32f. White solid (Yield 39%); m.p. 297 – 298oC. 1H NMR (400 MHz, DMSO) δH 11.79 (s, 1H, 
NH), 7.92 (s, 1H), 7.75 – 7.57 (m, 2H), 7.19 – 7.01 (m, 4H), 6.32 (t, J = 2.1 Hz, 2H), 1.87 (s, 3H, 
CH3); 
13C NMR (101 MHz, DMSO) δ 175.42, 164.30, 161.92 (d, J = 14.8 Hz), 160.97 (d, J = 15.3 
Hz), 145.27, 142.84, 139.25, 134.90, 131.52, 129.60, 128.42, 128.35, 122.63, 117.30, 110.23, 
99.72 (d, J = 19.1 Hz), 99.24 (d, J = 26.0 Hz), 12.30; HRMS (ESI) C20H13N2OF2
35Cl23Na [M+Na]
+ 
requires 393.0582, found 393.0592. Anal. C20H13N2OF requires C 64.79%, H 3.53%, N 7.56%, 
found C 64.66%, H3.69%, N 7.39%. 
Preparation of 5,7-difluoro-2-(2-fluoro-4-(1H-pyrrol-1-yl)phenyl)-3-methylquinolin-4(1H)-one 
32g. White solid (Yield 39%); m.p. 307oC. 1H NMR (400 MHz, DMSO) δH 11.82 (s, 1H, NH), 
7.84 (dd, J = 11.8, 1.9 Hz, 1H), 7.77 – 7.64 (m, 2H), 7.62 – 7.55 (m, 2H), 7.18 – 6.99 (m, 2H), 
6.40 – 6.23 (m, 2H), 1.79 (s, 3H, CH3); HRMS (ESI) C20H14N2OF3 [M+H]+ requires 355.1058, 
found 355.1074. Anal. C20H13N2OF3 requires C 67.79%, H 3.70%, N 7.91%, found C 66.94%, H 
3.68%, N 7.73%. 
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Preparation of (R)-5,7-difluoro-2-(4-(3-fluoropyrrolidin-1-yl)phenyl)-3-methylquinolin-4(1H)-
one 38a. White solid (45%); m.p. 313-314°C. NMR: 1H (400 MHz, DMSO) δ 11.47 (s, 1H), 7.38 
(d, J = 8.7 Hz, 2H), 7.18 (d, J = 9.3 Hz, 1H), 6.99 (ddd, J = 12.0, 9.6, 2.4 Hz, 1H), 6.73 (d, J = 8.7 
Hz, 2H), 5.50 (d, J = 54.1 Hz, 1H), 3.71 – 3.36 (m, 4H), 2.38 – 2.12 (m, 2H), 1.89 (s, 3H); 13C 
(101 MHz, DMSO) δ 175.38, 148.31, 147.92, 142.70, 130.35, 121.60, 116.19, 111.70, 110.56, 
99.39, 98.76, 94.49, 92.78, 54.48, 45.59, 32.14, 31.93, 12.58. ES HRMS: m/z found 359.1385, 
C20H18N2OF3 requires 359.1371; Anal. C20H17N2OF3 requires C 67.03%, H 4.78%, N 7.82%, 
found C 67.26%, H 4.73%, N 7.81%. 
Preparation of (S)-5,7-difluoro-2-(4-(3-fluoropyrrolidin-1-yl)phenyl)-3-methylquinolin-4(1H)-
one 38b. White solid (47%); m.p. 313-314°C. NMR: 1H (400 MHz, DMSO) δ 11.47 (s, 1H), 7.38 
(d, J = 8.6 Hz, 2H), 7.18 (d, J = 9.2 Hz, 1H), 6.99 (ddd, J = 12.0, 9.7, 2.4 Hz, 1H), 6.73 (d, J = 8.7 
Hz, 2H), 5.50 (d, J = 54.3 Hz, 1H), 3.69 – 3.36 (m, 4H), 2.36 – 2.13 (m, 2H), 1.89 (s, 3H); 13C 
(101 MHz, DMSO) δ 175.38, 148.32, 147.93, 142.78, 130.36, 121.60, 116.19, 111.70, 110.54, 
99.36, 98.76, 94.49, 92.78, 54.48, 45.59, 32.14, 31.93, 12.58. ES HRMS: m/z found 359.1381, 
C20H18N2OF3 requires 359.1371; Anal. C20H17N2OF3 requires C 67.03%, H 4.78%, N 7.82%, 
found C 67.25%, H 4.67%, N 7.86%. 
Preparation of 2-(4-(3,3-difluoroazetidin-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-one 
38c. White solid (33%); m.p. 316-318°C. NMR: 1H (400 MHz, DMSO) δ 11.54 (s, 1H), 7.43 (d, 
J = 8.4 Hz, 2H), 7.16 (d, J = 9.6 Hz, 1H), 7.01 (t, J = 10.8 Hz, 1H), 6.74 (d, J = 8.5 Hz, 2H), 4.37 
(t, J = 12.3 Hz, 4H), 1.86 (s, 3H).; 13C (101 MHz, DMSO) δ 175.39, 150.88, 147.53, 142.81, 
130.18, 124.67, 117.01, 116.50, 112.70, 110.53, 99.41, 98.90, 90.56, 74.81, 63.29, 12.44. ES 
HRMS: m/z found 363.1130, C19H15N2OF4 requires 363.1121; Anal. C19H14N2OF4 requires C 
62.98%, H 3.89%, N 7.73%, found C 63.03%, H 3.79%, N 7.71%. 
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Preparation of 2-(4-(3,4-difluoro-1H-pyrrol-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-
one 38d. White solid (38 mgs, 30 %). 1H NMR (400 MHz, DMSO) 11.78 (bs, 1H), 7.83 (d, J = 
8.8 Hz, 2H), 7.72 (d, J = 8.8 Hz, 4H), 7.14 (d, J = 9.6 Hz, 1H), 7.11 (dd, J = 11.0, 10.6 Hz, 1H), 
1.91 (s, 3H), 13C NMR (100 MHz, DMSO) δC 175.1, 146.8, 140.3, 131.8, 130.8, 118.7, 116.9, 
103.0, 12.3; MS (ES+) m/z 373 (M + H)+ HRMS calculated for 373.0964 C20H13N2OF4, found 
373.0965; Purity HPLC 98% (Method A) Rt = 2.60 min..    
Preparation of 2-(4-(3,4-difluoro-1H-pyrrol-1-yl)phenyl)-7-methoxy-3-methylquinolin-4(1H)-one 
38e. White solid (0.12 g, 32 %). 1H NMR (400 MHz, DMSO) 11.48 (bs, 1H), 8.02 (d, J = 9.2 Hz, 
1H), 7.75 (d, J = 8.8 Hz, 2H), 7.66 (m, 4H), 7.01 (s, 1H), 6.90 (d, J = 9.0 Hz, 1H), 3.82 (s, 3H), 
1.90 (s, 3H); 13C NMR (100 MHz, DMSO) δC 176.5, 161.9, 141.8, 141.1, 140.0, 138.9, 138.7, 
130.8, 127.2, 118.6, 118.0, 114.3, 113.3, 102.7, 102.5, 102.4, 99.2,. 55.7, 12.5; MS (ES+) m/z 367 
(M + H)+ HRMS calculated for 367.1258 C21H17N2O2F2, found 367.1257; Purity HPLC 99+% 
(Method A) Rt = 2.09 min. 
Preparation of 6-chloro-2-(4-(3,4-difluoro-1H-pyrrol-1-yl)phenyl)-7-methoxy-3-methylquinolin-
4(1H)-one 38f. White solid (0.11 g, 30 %). 1H NMR (400 MHz, DMSO) 11.75 (bs, 1H), 8.03 (s, 
1H), 7.71 (d, J = 8.8 Hz, 2H), 7.63 (m, 4H), 7.15 (s, 1H), 3.89 (s, 3H), 1.91 (s, 3H); 13C NMR (100 
MHz, DMSO) δC 175.1, 156.3, 139.7, 138.7, 130.8, 126.0, 118.5, 114.2, 102.7, 102.5, 102.4, 56.5, 
12.9; MS (ES+) m/z 401 (M + H)+ HRMS calculated for 401.0868 C21H16N2O2F2
35Cl, found 
401.0870; Purity HPLC 97% (Method A) Rt = 2.35 min.. 
Preparation of 5,7-difluoro-2-(4-(3-hydroxy-3-methylpiperidin-1-yl)phenyl)-3-methylquinolin-
4(1H)-one 38g. While solid (48%); m.p. decomposed at 284°C. NMR: 1H (400 MHz, DMSO) δ 
11.47 (s, 1H), 7.35 (d, J = 8.8 Hz, 2H), 7.16 (d, J = 9.2 Hz, 1H), 7.07 – 6.94 (m, 3H), 4.46 (s, 1H), 
3.30 – 3.02 (m, 4H), 1.88 (s, 3H), 1.86 – 1.75 (m, 1H), 1.63 – 1.48 (m, 3H), 1.17 (s, 3H); 13C (101 
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MHz, DMSO) δ 175.37, 163.50, 161.49, 152.33, 147.68, 142.79, 130.15, 123.19, 116.27, 114.64, 
110.56, 99.34, 98.82, 67.64, 59.76, 47.81, 37.73, 27.28, 22.10, 12.52. ES HRMS: m/z found 
385.1738, C22H23N2O2F2 requires 385.1728; Anal. C22H22N2O2F2 requires C 68.74%, H 5.77%, N 
7.29%, found C 68.49%, H 5.84%, N 7.39%.  
Preparation of 5,7-difluoro-2-(4-(3-hydroxy-3-methylpyrrolidin-1-yl)phenyl)-3-methylquinolin-
4(1H)-one 38h. White solid (50%); m.p. 288-290°C. NMR: 1H (400 MHz, DMSO) δ 11.43 (s, 
1H), 7.35 (d, J = 8.7 Hz, 2H), 7.18 (d, J = 10.1 Hz, 1H), 6.98 (ddd, J = 12.0, 9.6, 2.5 Hz, 1H), 6.62 
(d, J = 8.8 Hz, 2H), 4.85 (s, 1H), 3.48 – 3.36 (m, 2H), 3.24 (s, 2H), 2.01 – 1.92 (m, 2H), 1.89 (s, 
3H), 1.37 (s, 3H); 13C (101 MHz, DMSO) δ 175.38, 160.89, 155.31, 148.73, 148.07, 130.29, 
120.65, 116.06, 111.02, 99.38, 96.34, 94.24, 91.71, 75.74, 60.95, 55.28, 46.88, 26.29, 12.63. ES 
HRMS: m/z found 399.1391, C21H20N2O2F2
23Na requires 393.1391; Purity HPLC 98% (Method 
A) Rt = 2.25 min. 
Preparation of 5,7-difluoro-2-(4-(3-hydroxy-3-methylazetidin-1-yl)phenyl)-3-methylquinolin-
4(1H)-one 38i. White solid (43%); m.p. decomposed at 289°C.NMR: 1H (400 MHz, DMSO) δ 
11.48 (s, 1H), 7.35 (d, J = 8.6 Hz, 2H), 7.16 (d, J = 9.1 Hz, 1H), 6.99 (ddd, J = 12.0, 9.6, 2.4 Hz, 
1H), 6.58 (d, J = 8.6 Hz, 2H), 5.60 (s, 1H), 3.83 (d, J = 7.9 Hz, 2H), 3.69 (d, J = 7.7 Hz, 2H), 1.86 
(s, 3H), 1.48 (s, 3H); 13C (101 MHz, DMSO) δ 175.38, 160.90, 152.74, 147.89, 142.69, 136.81, 
134.24, 130.07, 122.72, 116.28, 111.45, 99.62, 98.81, 67.73, 66.17, 27.02, 12.52. ES HRMS: m/z 
found 379.1237, C20H18N2O2F2
23Na requires 379.1234; Anal. C20H18N2O2F2 requires C 67.41%, 
H 5.09%, N 7.86%, found C 67.18%, H 5.49%, N 7.24%. 
Preparation of (S)-2-(4-(2-((benzyloxy)methyl)pyrrolidin-1-yl)phenyl)-5,7-difluoro-3-
methylquinolin-4(1H)-one 38j. Cream solid (0.10 g, 20 %). 1H NMR (400 MHz, DMSO) 10.60 
(bs, 1H), 7.33 (m, 6H), 7.22 (d, J = 8.8 Hz, 2H), 6.56 (dd, J = 11.0, 10.6 Hz, 1H), 6.44 (d, J = 8.8 
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Hz, 2H), 4.52 (s, 2H), 3.84 (m, 1H), 3.51 (dd, J = 8.8, 4.5 Hz, 1H), 3.30 (m, 2H), 3.05 (m, 1H), 
2.05 (m, 4H), 1.92 (s, 3H);  13C NMR (100 MHz, DMSO) δC 177.1, 148.8, 147.9, 138.1, 129.7, 
128.4, 127.8, 127.6, 121.5, 117.2, 111.3, 99.2, 73.4, 70.0, 58.2, 48.3, 28.9, 23.2, 12.4; MS (ES+) 
m/z 461 (M + H)+ HRMS calculated for 461.2041 C28H27N2O2F2, found 461.2055.    
General procedure for the preparation of compounds 39a-c.   
Preparation of (S)-5,7-difluoro-2-(4-(2-(hydroxymethyl)pyrrolidin-1-yl)phenyl)-3-
methylquinolin-4(1H)-one 39a. Cream solid (50 mgs, 90 %). 1H NMR (400 MHz, DMSO) 11.45 
(bs, 1H), 7.35 (d, J = 8.8 Hz, 2H), 7.20 (dd, J = 8.0, 4.5 Hz, 1H), 7.01 (dd, J = 11.0, 10.6 Hz, 1H), 
6.75 (d, J = 8.8 Hz, 2H), 4.90 (m, 1H), 3.81 (m, 1H), 3.75 (m, 1H), 3.50 (m, 1H), 3.22 (m, 1H), 
3.10 (m, 1H), 2.03 (m, 4H), 1.92 (s, 3H); 13C NMR (100 MHz, DMSO) C 175.4, 148.4, 148.0, 
130.3, 121.1, 116.1, 111.7, 99.3, 61.3, 60.5, 48.5, 28.3, 23.0, 12.6; MS (ES+) m/z 371 (M + H)+ 
HRMS calculated for 371.1571 C21H21N2O2F2, found 371.1568; Purity HPLC 96% (Method A) Rt 
= 2.25 min.    
Preparation of (R)-5,7-difluoro-2-(4-(2-(hydroxymethyl)pyrrolidin-1-yl)phenyl)-3-
methylquinolin-4(1H)-one 39b. Light yellow solid (0.065 g, 85 %).  1H NMR (400 MHz, DMSO) 
11.44 (bs, 1H), 7.35 (d, J = 8.8 Hz, 2H), 7.17 (d, J = 8.0 Hz, 1H), 6.99 (dd, J = 11.0, 10.6 Hz, 1H), 
6.75 (d, J = 8.8 Hz, 2H), 4.84 (dd, J = 5.8, 5.8 Hz, 1H), 3.77 (m, 1H), 3.51 (m, 1H), 3.42 (m, 1H), 
3.25 (m, 1H), 3.08 (m, 1H), 1.98 (m, 4H), 1.89 (s, 3H); 13C NMR (100 MHz, DMSO) C 175.7, 
148.8, 148.0, 130.3, 121.1, 116.2, 111.7, 99.9, 61.5, 60.5, 28.5, 23.6, 12.6; MS (ES+) m/z 371 (M 
+ H)+ HRMS calculated for 371.1571 C21H21N2O2F2, found 371.1572; Purity HPLC 97% (Method 
A) Rt = 2.24 min. 
Preparation of (R)-2-(4-(3-(aminomethyl)pyrrolidin-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-
4(1H)-one 39c. White solid (21 mgs, 93 %). 1H NMR (400 MHz, DMSO) 11.48 (bs, 1H), 7.40 (m, 
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1H), 7.38 (d, J = 8.8 Hz, 2H), 7.21 (d, J = 8.4 Hz, 1H), 6.99 (dd, J = 11.0, 10.6 Hz, 1H), 6.86 (d, 
J = 8.8 Hz, 2H), 4.09 (m, 1H), 3.20 (m, 1H), 2.99 (m, 1H), 2.51 (d, J = 10.4 Hz, 1H), 2.31 (dd, J 
= 14.4, 10.9 Hz, 1H), 2.13 (m, 1H), 1.98 (s, 3H), 1.82 (m, 2H), 1.63 (m, 2H); 13C NMR (100 MHz, 
DMSO) C 175.4, 147.8, 130.4, 116.2, 112.0, 111.6, 99.7, 56.5, 56.2, 48.3, 34.6, 28.5, 12.6; MS 
(ES+) m/z 370 (M + H)+ HRMS calculated for 370.1731 C21H22N3OF2, found 370.1738; Purity 
HPLC 96% (Method A) Rt = 1.61 min. 
Preparation of 2-(4-(3,3-difluoropyrrolidin-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-
one 42a. White solid (56%); m.p. decomposed at 316°C. NMR: 1H (400 MHz, DMSO) δ 7.41 (d, 
J = 8.7 Hz, 2H), 7.17 (d, J = 9.0 Hz, 1H), 7.01 (ddd, J = 12.0, 9.6, 2.4 Hz, 1H), 6.78 (d, J = 8.8 Hz, 
2H), 3.79 (t, J = 13.3 Hz, 1H), 3.56 (t, J = 7.2 Hz, 1H), 2.59 (tt, J = 14.5, 7.3 Hz, 1H), 1.87 (s, 1H); 
13C (101 MHz, DMSO) δ 175.38, 164.09, 148.09, 147.72, 142.82, 130.34, 129.16, 126.71, 122.79, 
116.32, 111.98, 111.61, 99.37, 98.82, 54.96, 45.75, 33.72, 12.54. ES HRMS: m/z found 399.1093, 
C20H16N2OF4
23Na requires 399.1096; Anal. C20H16N2OF4 requires C 63.83%, H 4.29%, N 7.44%, 
found C 63.49%, H 4.31%, N 7.28%. 
Preparation of 2-(4-(3,3-difluoropiperidin-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-one 
42b. White solid (47%); m.p. decomposed at 297°C. NMR: 1H (400 MHz, DMSO) δ 11.54 (s, 1H), 
7.39 (d, J = 8.8 Hz, 2H), 7.20 – 7.11 (m, 3H), 7.01 (ddd, J = 12.0, 9.6, 2.4 Hz, 1H), 3.65 (t, J = 
11.9 Hz, 2H), 3.43 – 3.37 (m, 2H), 2.16 – 2.01 (m, 2H), 1.87 (s, 3H), 1.85 – 1.75 (m, 2H); 13C (101 
MHz, DMSO) δ 175.38, 152.75, 150.88, 147.47, 142.69, 130.26, 124.51, 121.44, 116.43, 115.09, 
113.88, 110.51, 99.67, 98.87, 53.21, 52.92, 46.93, 32.09, 21.59, 12.47. ES HRMS: m/z found 
391.1441, C21H19N2OF4 requires 391.1434; Anal. C21H18N2OF4 requires C 64.61%, H 4.65%, N 
7.18%, found C 64.06%, H 4.61%, N 7.05%. 
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Preparation of (R)-N-(tert-butyl)-1-(4-(3-methyl-4-oxo-1,4-dihydroquinolin-2-
yl)phenyl)pyrrolidine-2-carboxamide 45a. Pale yellow powder (yield 20%); m.p. 164-166 oC 1H 
NMR (400 MHz, CDCl3-d6) δH 11.11 (s, 1H,NH), 7.43 (d, 2H, J = 8.6 Hz, Ar), 7.34 (d, 1H, J = 
9.6 Hz, Ar), 6.71-6.61 (m, 1H, Ar), 6.55 (d, 2H, J = 8.6 Hz, Ar), 6.28 (s, 1H, NH), 3.59 (t, 1H, J = 
7.2 Hz, CH), 2.99 (dd, 1H, J = 15.4 Hz, 8.9 Hz, CH2), 2.89 (d, 1H, J = 8.6 Hz, CH2), 2.03 (s, 3H, 
CH3), 1.92-1.65 (m, 4H, CH2), 1.34 (m, 9H, CH3) 
13C NMR (100 MHz, CDCl3-d6) δc 173.1, 148.0, 
130.1, 125.3, 117.7, 113.1, 64.6, 51.3, 49.8, 31.4, 28.6, 24.0, 12.3 MS (ES+), [M + Na] + (100)   
462.2 HRMS calculated for   462.1969 C25H27O2N3F2Na, found 462.1955; Anal. C25H27N3O2F2 
requires C 68.32%, H 6.19%, N 9.56%, found C 68.13%, H 6.10%, N 9.11%. 
Preparation of (R)-1-(4-(5,7-difluoro-3-methyl-4-oxo-1,4-dihydroquinolin-2-yl)phenyl)-N,N-
dimethylpyrrolidine-2-carboxamide 45b. Pale yellow powder (Yield 34%); m.p. 176-178 o C. 1H 
NMR (400 MHz, CDCl3-d6) δH 10.40 (s, 1H, NH), 7.24-7.22 (m, 1H,Ar), 7.12 (d, 2H, J = 8.6 Hz, 
Ar), 6.73-6.56 (m, 1H, Ar), 6.13 (d, 2H, J = 8.6 Hz, Ar), 4.22 (dd, 1H.J = 8.8 Hz, 2.1 Hz, CH), 
3.46-3.39 (m, 1H, CH2), 3.25 (dd, 1H, J = 16.0 Hz, 8.4 Hz, CH2), 3.16 (s, 3H, NCH3), 2.85 (s, 3H, 
NCH3), 2.35-2.23 (m, 1H, CH2), 2.20-1.95 (m, 3H, CH2), 1.90 (s, 3H, CH3) 
13C NMR (100 MHz, 
CDCl3-d6) δc 177.7, 172.7, 147.9, 129.6, 122.1, 117.1, 111.0, 58.6, 48.5, 36.9, 36.0, 30.5, 23.6, 
15.3, 12.5 MS (ES+), [M + Na] + (100)   434.2 HRMS calculated for  434.1656 C23H23O2N3F2Na, 
found 434.1669; Purity HPLC 97% (Method B) Rt = 1.95 min. 
Preparation of (R)-1-(4-(5,7-difluoro-3-methyl-4-oxo-1,4-dihydroquinolin-2-yl)phenyl)-N-
(tetrahydro-2H-pyran-4-yl)pyrrolidine-2-carboxamide 45c. Pale yellow powder (yield 25%) m.p 
228-230 oC 1H NMR (400 MHz, CDCl3-d6) δH 10.82 (s, 1H, NH), 7.36 (d, 2H, J = 8.7 Hz, Ar), 
7.25 (d, 1H, J = 9.6 Hz, Ar), 6.68-6.59 (m, 1H, Ar), 6.56 (s, 1H, NH), 6.53 (d, 2H, J = 8.7 Hz, Ar), 
4.06-3.82 (m, 2H, CH/CH2), 3.66-3.56 (m, 1H, CH2), 3.52-3.39 (m, 3H, CH2),3.30 (d, 1H, J = 6.7 
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Hz, CH2), 3.11-3.02 (m, 1H, CH2), 2.05-1.71 (m, 9H, CH2/CH3), 1.53-1.30 (m, 2H, CH2) 
13C NMR 
(100 MHz, CDCl3-d6) δc 177.1, 173.1, 148.0, 147.2, 130.0, 124.9, 117.6, 112.9, 66.6, 65.9, 64.1, 
49.7, 46.0, 32.9, 31.4, 24.1, 15.3, 12.3 MS (ES+), [M + Na] + (100) 490.2 HRMS calculated for   
490.1018 C26H27O3N3F2Na, found 490.1932; Purity HPLC 93% (Method B) Rt = 1.92 min. 
Preparation of (R)-5,7-difluoro-3-methyl-2-(4-(2-(morpholine-4-carbonyl)pyrrolidin-1-
yl)phenyl)quinolin-4(1H)-one 45d. Pale yellow powder (yield 18%); m.p. 236-238 oC.  1H NMR 
(400 MHz, CDCl3-d6) δH 10.26 (s, 1H, NH), 7.20 (d, 1H, J = 9.2 Hz, Ar), 7.14 (d, 2H, J = 8.6 Hz, 
Ar), 6.67-6.59 (m, 1H, Ar), 6.17 (d, 2H, J = 8.6 Hz, Ar), 4.44-4.37 (m, 1H, CH), 3.78 (dd, 1H, 
CH2), 3.74-3.55 (m, 6H, CH2), 3.46-3.35 (m, 2H, CH2), 3.27 (dd, 1H, J = 16.1 Hz, 8.3 Hz, CH2), 
2.36-2.24 (m, 1H, CH2), 2.18-2.04 (m, 2H, CH2), 2.03-1.96 (m, 1H, CH2), 1.90 (s, 3H, CH3) 
13C 
NMR (100 MHz, CDCl3-d6) δc 171.2, 147.7, 147.0, 129.6, 122.2, 117.2, 111.1, 67.0, 66.5, 58.7, 
48.5, 45.8, 42.5, 30.8, 23.6, 12.4 MS (ES+), [M + Na] + (100)   476.2 HRMS calculated for 
476.1762 C25H25O3N3F2Na, found 476.1778; Purity HPLC 93% (Method B) Rt = 1.90 min. 
Preparation of (R)-5,7-difluoro-2-(4-(2-(4-fluoropiperidine-1-carbonyl)pyrrolidin-1-yl)phenyl)-
3-methylquinolin-4(1H)-one 45e. Pale yellow powder (yield  24%); m.p. 238-240 oC. 1H NMR 
(400 MHz, CDCl3-d6) δH 10.21 (s,1H, NH), 7.24-7.08 (m, 3H, Ar), 6.63 (t, 1H, Ar), 6.18 (dd, 2H, 
J = 7.7 Hz, 5.0 Hz, Ar), 5.04-4.81 (m, 1H, CHF), 4.44 (d, 1H, CH), 3.88-5.59 (m, 3H, CH2), 3.58-
3.32 (m, 1H, CH2), 3.31-3.19 (m, 1H, CH2), 2.40-2.24 (m, 1H, CH2), 2.18-1.61 (m, 11H, CH2) 
13C 
NMR (100 MHz, CDCl3-d6) δc 171.4, 148.0, 147.7, 129.6, 122.4, 116.9, 111.1, 65.9, 58.8, 48.5, 
38.8, 30.9, 23.9, 12.4. MS (ES+), [M + Na] + (100) 492.2 HRMS calculated for   492.1875 
C26H26O2N3F3Na, found 492.1872; Purity HPLC 96% (Method A) Rt = 2.20 min. 
Preparation of 4(R)-1-(4-(5,7-difluoro-3-methyl-4-oxo-1,4-dihydroquinolin-2-yl)phenyl)-N,N-
dimethylazetidine-2-carboxamide 45f. White solid (0.056 g, 14%). δH [400 MHz, (CD3)2SO] 1.87 
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(3 H, s, CH3C), 2.30-2.40, 2.60-2.75 (2 H, 2m, CCH2C),2.88, 2.94 (6 H, 2s, Me2N), 3.72, 3.93 (2 
H, 2m, CH2N), 4.92 (1 H, approx. t, CHN), 6.51 (2 H, d, ArH), 7.00 (1 H, m, ArH), 7.17 (1 H, m, 
ArH), 7.33 (2 H, d, ArH) and 11.49 (1 H, br s, NH); δC [100 MHz, (CD3)2SO] 12.5, 22.1, 35.4, 
35.8, 49.0, 63.2, 111.5, 116.3, 123.0, 129.8, 148.0, 151.9, 170.5 and 175.4; not all the aromatic 
carbons were seen; m/z (ES +ve mode) 398 (MH+, 100%); Found: m/z, 398.1667. C22H22N3O2F2 
requires m/z, 398.1680; Anal. C22H21N3O2F2 requires C 66.49%, H 5.33%, N 10.57%, found C 
66.15%, H 5.36%, N 9.88%. 
Preparation of (R)-N-(tert-butyl)-1-(4-(5,7-difluoro-3-methyl-4-oxo-1,4-dihydroquinolin-2-
yl)phenyl)azetidine-2-carboxamide 45g. Pale yellow powder (0.033 g, 12%). δH [400 MHz, 
CDCl3] 1.42 (9 H, s, Me3C), 2.00 (3 H, s, CH3C=), 2.20-2.30 (2 H, m, CCH2C), 3.26 (1 H, m), 
3.58 (1 H, m), 3.95 (1 H, m), 6.52 (2 H, d, ArH), 6.60-6.70 (1 H, m, ArH), 7.19 (1 H, m, ArH), 
7.40 (2 H, d, ArH) and 10.43 (1 H, br s, NH); m/z (CI, methane) 426 (MH+, base peak). Found: 
m/z, 426.1988. C24H26F2N3O2 requires m/z, 426.1986; Anal. C24H25N3O2F2 requires C 67.75%, H 
5.92%, N 9.88%, found C 67.26%, H 5.88%, N 9.56%. 
Preparation of 2-(4-(3,3-difluoropyrrolidin-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4-yl 
acetate 46. To a suspension of 2-(4-(3,3-difluoropyrrolidin-1-yl)phenyl)-5,7-difluoro-3-
methylquinolin-4(1H)-one (280mg, 0.74mmol) in THF (15ml), tBuOK (172mg, 1.5mmol) was 
added. The resulting mixture was kept stirring at room temperature for 1 hour. After that, excess 
acetyl chloride (0.2ml) was added and the reaction mixture was kept stirring for 3 hours at room 
temperature. After that, H2O (15ml) was used to quench the reaction and Et2O (50ml) was used to 
dilute the mixture. Organic layer was separated from the water layer, and DCM/MeOH (1:1, 20ml) 
was added to the organic layer to dissolve any precipitation. The organic solution was dried with 
MgSO4 and concentrated in vacuo to give the crude product. The crude product we purified by 
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flash column chromatograph eluting with 20% EtOAc in hexane to give the title product a pale 
yellow solid (290mg, 94%). δH [400 MHz, CDCl3] 7.72 – 7.53 (m, 3H), 6.99 (dd, J = 15.1, 5.7 Hz, 
1H), 6.66 (d, J = 8.6 Hz, 2H), 3.75 (t, J = 13.2 Hz, 2H), 3.61 (t, J = 7.1 Hz, 2H), 2.54 (ddd, J = 
21.2, 14.0, 7.3 Hz, 2H), 2.46 (s, 3H), 2.32 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 168.52, 163.55, 
161.69 (dd, J = 249.3, 14.3 Hz), 157.00 (dd, J = 258.3, 14.3 Hz), 150.99 (t, J = 1.8 Hz), 149.05 
(dd, J = 14.2, 2.6 Hz), 147.41, 130.57, 128.55, 128.04, 125.58, 121.90, 111.53, 109.74 (dd, J = 
20.6, 5.0 Hz), 109.51 (dd, J = 9.3, 1.8 Hz), 103.05 (dd, J = 29.3, 25.9 Hz), 55.33 (t, J = 31.6 Hz), 
45.54 (t, J = 3.2 Hz), 34.28 (t, J = 24.0 Hz), 20.71, 13.71;  HRMS (ES) C22H18N2O2F3
23Na 
[M+Na]+ requires 441.1202, found 441.1212;  Anal. C22H18N2O2F4 requires C 63.16%, H 4.34%, 
N 6.70%, found C 62.77%, H 4.29%, N 6.53%. 
Biology 
Drug susceptibility assays using replicating and hypoxic Mtb - For drug susceptibility assays, 
aerobic cultures of Mtb H37Rv were cultured as described previously 14. Cultures were grown 
until a mid-log growth phase was reached (Middlebrook 7H9 broth with addition of 10% albumin–
dextrose–catalase solution (Becton Dickinson), 0.2% [vol/vol] glycerol and 0.05% [vol/vol] 
Tween 80). Hypoxic cultures of Mtb were produced using the same growth media but the method 
described by Wayne and Hayes was utilised 58, where oxygen supply was limited over six weeks 
and cultures were mixed using 8-mm Teflon-coated magnetic stirring bars (120 rpm, 37°C). 
The effectiveness of test drugs to prevent Mtb growth was determined using a microplate 
AlamarBlue assay (MABA) as described previously 14. A range of test drug concentrations (10 
µM to 0.08 µM, 2% DMSO)  were co-incubated with replicating Mtb (OD 0.01, 7 days, 37°C) 
followed by a MABA. Measurements of well absorbance at 570 and 600 nm recorded using an 
Opsys MR plate reader were determined to calculate IC50 values for the inhibitors. For anaerobic 
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cultures, co-incubations of hypoxic Mtb and test drug were performed as described for replicating 
Mtb, however the plates were sealed within GasPak EZ pouches containing an indicator to ensure 
anaerobic conditions were maintained. The plates were subsequently incubated anaerobically (7 
days, 37°C) before being moved to an aerobic environment for a further 7 days. The IC50 values 
were calculated as described for aerobic cultures. 
 
In vitro Metabolic Stability - Mixed pools of microsomes from multiple donors were purchased 
from BD Biosciences, USA (Human, Rat and Mouse) (protein content 20 mg/mL).  Compounds 
of interest were tested at 10, 1 and 0.1 µM with a final concentration of microsomal protein of 1 
mg/mL.  The reaction was initiated by the addition of NADPH (1 mM) and samples were incubated 
for up to 60 min at 37°C in a shaking incubator.  The reaction was terminated at 0, 10, 30 and 60 
min by the addition of ice cold ACN/MeOH (50:50) spiked with internal standard.  Sample 
preparation for mass spectrometry involved the addition of an equivalent amount of water to each 
sample before extraction using ethyl acetate (3 x 500 µL).  The organic layer was then dried under 
nitrogen before reconstitution in MeOH/H20 (50:50).  
Cytotoxicity assay in HEPG2 using MTT - The cellular toxicity of test compounds were 
determined using the MTT assay, with modifications, using HEPG2 cells which were either 
resistant (cultured using glucose-containing media) or susceptible (cultured using galactose-
containing media) to mitochondrial-toxicity-induced cell death 59, 60. Briefly, HepG2 cells cultured 
in glucose media (high-glucose Dulbecco’s modified Eagle’s medium (DMEM) containing 25 mM 
glucose and 1 mM sodium pyruvate, supplemented with 5 mM HEPES, 10% [vol/vol] fetal bovine 
serum (FBS), and 100 µg/ml penicillin-streptomycin) or galactose media (glucose-free DMEM 
supplemented with 10 mM galactose, 5 mM HEPES, 10 % [vol/vol] FBS, 1 mM sodium pyruvate, 
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and 100 µg/ml penicillin-streptomycin) were added to 96-well plates (60 µl, 1 x 104 cells/well) and 
incubated for 24 hours.  Log-range concentrations of each test compound (1-100 µM) were then 
added to the plates and a further incubation of 24 hours performed. Plates were subsequently 
incubated for 2 hours in the presence 1 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution. Cell lysis solution (50 µL, 50% [vol/vol] 
dimethylformamide in distilled water, 20 % [wt/vol] sodium dodecyl sulphate) was added to wells 
and plates were wrapped in metallic foil and mixed at 60 rpm for 2 hours at room temperature.  
Well absorbance at 560 nm was determined using a Varioskan plate reader (ThermoScientific) and 
were used to determine IC50 values using a four parameter logistic function using Prism 5 software.  
All incubations were performed at 37 ˚C in a CO2 incubator and compounds were solubilised in 
DMSO (1% [vol/vol] final concentration).  The cytotoxic control compounds rotenone (0.001 µM 
– 1 µM, toxic to mitochondria) and tamoxifen (1-100 µM, no specific mitochondrial toxicity) were 
included as controls, as was a drug-free control containing 1% [vol/vol] DMSO. 
Caco-2 transepithelial drug transport - Caco-2 monolayer experiments were performed as 
previously described 61, with modifications. When confluent, Caco-2 cells were seeded onto 
polycarbonate membrane transwells at a density of 2.6 X 105 cells/cm2 (DMEM, 15% [vol/vol] 
FCS) and incubated (37°C, 5% CO2) for 16 hours. Following this incubation, media was replaced 
to remove dead cells and to prevent the formation of multiple layers of cells settling on the filter. 
Plate media was changed every 48 hours and plates used in experiments 21 days from initial 
seeding. Monolayer integrity was checked using a MillicellERS instrument (Millipore) to 
determine the trans-epithelial electrical resistance (TEER) across the monolayer. A TEER of more 
than 400 Ω/cm2 was deemed acceptable. 
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On the day of the experiment, the TEER was assessed and the media replaced with warm transport 
buffer (HBSS, 25 mM HEPES, 0.1% [wt/vol] bovine serum albumin, pH 7) and allowed to 
equilibrate (37°C, 30 minutes). The transport buffer in the chambers was replaced with transport 
buffer containing either the test compound or the control drug verapamil (5 µM). Samples (50 µL) 
were taken from the receiver compartment at 0, 60, 120 and 180 minutes and replaced with an 
equal volume of transport buffer. Samples were analysed using LC-MS/MS. Data were used to 
determine apparent permeability (Papp, 10
-6 cm/s) for each direction and efflux ratio (ratio of 
basolateral to apical Papp compared with apical to basolateral Papp). Papp was calculated using the 
following equation as described previously 62: 
Papp = (dQ / dt) x V 
A x C0 
dQ / dt is the change in drug concentration in the receiver chamber over time (nM/s); V is the 
volume in the receiver compartment (mL); A is the total surface area of the transwell membrane 
(cm2); C0 is the initial drug concentration in the donor compartment (nM); and Papp is the apparent 
permeability (x10-6 cm/s).  
Plasma protein binding using equilibrium dialysis - The extent of plasma protein binding for 
each test compounds was determined by equilibrium dialysis. Test compound was added to human 
plasma which was mixed and heated (1 µM, 1% [vol/vol] DMSO, 37°C). Regenerated cellulose 
membranes (5000 Daltons, Harvard Apparatus) were soaked in phosphate buffer for 5 minutes and 
placed within Fast Micro-Equilibrium Dializers (Harvard Apparatus). One millilitre plasma 
containing the test drug was added to the first compartment, and 1 mL phosphate buffer (1% 
[vol/vol] DMSO, 37°C) was added to the second compartment. Equilibrium dialysis was 
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undertaken by incubation (18 hours, 37°C) and samples were removed from each compartment for 
LC-MS/MS analysis. 
Plasma Stability - Compounds were incubated in rat or human plasma (1 µM) at 37 °C for up to 
3 h.  At various time-points (0, 10, 30, 60, 120 and 180 min) an aliquot (100 µL) was taken and 
the reaction was terminated by the addition of ice cold ACN/MeOH (300 µL, 50%:50% [vol/vol]) 
spiked with internal standard.  Samples underwent centrifugation to remove the protein precipitate 
and were analysed directly using LC-MS/MS analysis. 
In vitro CYPP450 Inhibition - CYPP450 VIVID® inhibition kits were purchased from Invitrogen 
Life Technologies™.  Briefly, compounds were tested at a final concentration of 10, 1 and 0.1 µM 
alongside a relevant positive control for the isoform of interest and a solvent control.  The assay 
utilised a substrate, specific to the isoform, which produced a fluorescent metabolite as it 
underwent oxidation by the P450 enzyme.  Inhibition of the enzyme led to reduced fluorescent 
output.  The assay was carried out in kinetics mode, with a reading being taken every minute for a 
total of 1 h. 
Pharmacokinetic Studies in Rats - Male Wistar rats (180 – 250 g) (n=4) were purchased from 
Charles River Laboratories, UK and allowed to acclimatise for 1 week in controlled conditions (23 
± 3 °C; relative humidity 50 ± 10 %; light-dark cycle 12 h). Animals were provided with feed 
pellet and filtered water ad libitum.  Each rat received an oral dose of the relevant compound (10 
or 50 mg/kg) in PEG400 (100 %) (5 mL/kg) via gavage needle or an IV injection of the relevant 
compound (0.5 mg/kg) in 5% PEG400 and 5% Solutol in water.  At various time-points the rats 
were anaesthetised using isoflurane and a blood sample (< 300 µL) was taken from a superficial 
vein in the tail.  The blood was immediately stored on ice before undergoing centrifugation at 
13,000 rpm, for 10 minutes.  An aliquot of 100 µL plasma was removed and added to ACN/MeOH 
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(300 µL, 50%:50% [vol/vol]) spiked with internal standard.  Samples were then analysed using 
LC-MS/MS within 24 hours of obtaining the final sample. 
PK data were modelled using the package Pmetrics® 63 utilising a one compartment gut absorption 
model. Separate doses were modelled separately to differentiate the effect of dose upon the 
pharmacokinetic profile of each compound.  
LC-MS/MS - Drug concentration analyses were performed on a TSQ Quantum Access mass 
spectrometer (Thermo, UK). Chromatographic separation for all test compounds and control 
compounds was performed at 30˚C on a Fortis C-18 3 µm column (50 X 2.1 mm i.d., Fortis 
technologies, UK). Mobile phases were solution A (100% acetonitrile) and solution B (100% LC-
MS/MS-grade water, 0.05% formic acid) and flow rate was 0.3 mL/min. Separation was achieved 
with a gradient elution beginning with 90% solution D and 10% solution A, which was maintained 
for 1 minute. Solution A was then gradually increased to 80% over 1.9 minutes and maintained for 
a further 1.4 minutes. Solution B was increased to 90% over 0.7 minutes and maintained for 0.2 
minutes, giving a total run time of 5.2 minutes. Robustness of analyses were assessed using 
standard concentration curves and quality control concentrations, where concentration standard 
deviations were required to be within 20% for generated results to be accepted.   
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ABBREVIATIONS 
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TB – tuberculosis, MDR – multi-drug resistant, XDR – extensively drug resistant, Mtb – 
Mycobacterium tuberculosis, NADH - Nicotinamide adenine dinucleotide, ETC – electron 
transport chain, ATP - Adenosine triphosphate, ETF – electron transferring flavoprotein, FRD – 
fumarate reductase, nar – nitrate reductase, HTS – high throughput screen, DMPK – drug 
metabolism and pharmacokinetics, SAR – structure activity relationship, DMF – dimethyl 
formamide, GSK – Glaxosmithkline, NBS – N-bromo succinamide, DCM – dichloromethane, 
PCC - pyridinium chlorochromate, EDC -1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, NHS 
– N-hydroxy succinamide, GLU – glucose, PPB – plasma protein binding, CL - clearance, AUC- 
area under the curve, TI – therapeutic index, hERG - human Ether-à-go-go-Related Gene, NC – 
not calculated, ND – not determined, ID – identification, M – metabolite, SD – Sprague Dawley, 
HPLC – High performance liquid chromatography, TLC – thin layer chromatography, DMSO – 
dimethyl sulfoxide, NADPH - nicotinamide adenine dinucleotide phosphate, MTT - 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, DMEM - Dulbecco's Modified Eagle's 
Medium, FBS – fetal bovine serum, HEPES - (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid, FCS – fetal calf serum, TEER - trans-epithelial electrical resistance, HBSS – Hank’s balance 
salt solution, LC-MS – Liquid chromatograph-mass spectrometry.  
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